Regulation of Phosphodiesterases by profibrotic regulators by Kolosionek, Ewa Julia
  
 
 
 
Regulation of Phosphodiesterases by profibrotic regulators 
 
 
 
 
 
 
 
Inaugural Dissertation 
submitted to the 
Faculty of Medicine 
in partial fulfillment of the requirements 
for the PhD-Degree 
of the Faculties of Veterinary Medicine and Medicine 
of the Justus Liebig University Giessen 
 
 
by 
Kolosionek, Ewa Julia 
of 
Wroclaw, Poland 
 
 
 
Giessen 2008 
 
 
  
From the Department of Medicine 
Director / Chairman: Prof. Dr. Werner Seeger 
of Medicine of the Justus Liebig University Giessen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First Supervisor and Committee Member:  
Second Supervisor and Committee Member:  
Committee Members: 
Date of Doctoral Defense: 
 
Table of context 
________________________________________________________________________ 
 I 
I. Table of context 
I. Table of context I 
II. List of Figures IV 
III. List of Tables VI 
IV. List of abbreviations VII 
V. Summary IX 
VI. Zusammenfassung XI 
1 1.Introduction 1 
1.1 Epithelial to mesenchymal transition 1 
1.1.1 Characteristic of epithelial to mesenchymal transition 1 
1.1.2 Induction of EMT 3 
1.1.3 TGF-β and its role during EMT 3 
1.1.4 EMT in embryo and adults 5 
1.1.4.1 EMT in development 5 
1.1.4.2 EMT in wound healing 5 
1.1.4.3 EMT in cancer 5 
1.1.4.4 EMT in fibrosis 6 
1.2 Phosphodiesterases 7 
1.2.1 Nomenclature of Phosphodiesterases 7 
1.2.2 Classification of Phosphodiesterases 7 
1.2.2.1 cGMP 7 
1.2.2.2 cAMP 8 
1.2.3 Structure of Phosphodiesterases 10 
1.2.4 Cyclic nucleotide recognition and hydrolysis 10 
1.2.5 Biochemical characteristics and structure of Human PDE Families 10 
1.2.6 Phospodiesterase 4 family 12 
1.2.6.1 General structure 12 
1.2.6.2 PDE4 interactions 13 
1.2.6.3 PDE4 regulation 15 
1.2.6.4 PDE4 inhibitors 16 
Table of context 
________________________________________________________________________ 
 II 
2 Aim of the study 18 
3. Materials and methods 19 
3.1. Materials 19 
3.1.1. Equipment 19 
3.1.2. Reagents 21 
3.2. Methods 23 
3.2.1. RNA isolation 23 
3.2.2. Reverse transcriptase reaction 23 
3.2.3. Polymerase chain reaction 24 
3.2.4. Agarose gel electrophoresis 25 
3.2.5. Protein isolation 25 
3.2.6. Protein quantification 25 
3.2.7. SDS polyacrylamide gel electrophoresis 25 
3.2.8. Immunoblotting 26 
3.2.9. Protein blotting 27 
3.2.10. Protein detection 27 
3.2.11. Densitometry 28 
3.2.12. PDE activity assay 28 
3.2.13. Immunocytochemistry 29 
3.2.14. Reactive oxygen species measurements 30 
3.2.15. Statistical analysis 30 
3.2.16. Cell culture condition 30 
4. Results 32 
4.1. Cell morphology and phenotype during EMT in A549 cells 32 
4.1.1. Morphological changes 32 
4.1.2. Expression analysis of epithelial markers 32 
4.1.3. Expression analysis of mesenchymal markers 34 
4.2. PDE expression during TGF-β1 induced EMT 36 
4.3. PDE activity during TGF-β1 induced EMT 38 
4.4. Expression of PDE4 isoforms in TGF-β1 induced EMT 39 
4.5. Localization of PDE4 isoforms in TGF-β1 induced EMT 40 
Table of context 
________________________________________________________________________ 
 III 
4.6. Effect of PDE4 inhibition on TGF-β1 induced EMT 41 
4.7. Effect of PDE4 inhibition on Smad signaling 44 
4.8. Effect of PDE4 inhibition on TGF-β1 induced ROS production 46 
4.9. Effect of ROCK inhibition 47 
5. Discussion 48 
5.1. TGF-β1 induced EMT in A549 cells 48 
5.2. PDEs in TGF-β1 induced EMT in A549 cells 49 
5.2.1. PDE expression in TGF-β1 induced EMT 50 
5.2.2. PDE activation in TGF-β1 induced EMT 51 
5.2.3. PDE4 family in TGF-β1 induced EMT in A549 cells 52 
5.2.3.1. PDE4 expression 52 
5.2.3.2. PDE4 localization 52 
5.2.4. PDE4 inhibition in TGF-β1 induced EMT 53 
5.2.5. PDE4 inhibition and Smad signaling 56 
5.3. PDE4 family and ROS generation 58 
5.4. PDE4 family and Rho kinases 59 
5.5. Conclusions and future directions 60 
6. Appendix 63 
6.1. List of primers used for PCR amplification 63 
6.2. List of primary antibodies 64 
6.3. List of secondary antibodies 64 
7. References 65 
8. Declaration 74 
9. Curriculum Vitae 75 
10.   Acknowledgements 79 
 
List of figures 
________________________________________________________________________ 
 IV 
II. List of Figures 
 
Figure 1.1. Basic mechanisms of epithelial-to-mesenchymal transition (EMT) 
Figure 1.2. Transforming growth factor β1 (TGF- β1) signaling pathway 
Figure 1.3. cGMP synthesis and hydrolysis 
Figure 1.4. cAMP synthesis and hydrolysis 
Figure 1.5. AC-cAMP-PKA signaling pathway 
Figure 1.6. PDE4 family structure 
Figure 1.7. Structure of Rolipram  
Figure 4.1. Effects of TGF-β1 on cell morphology 
Figure 4.2. Effect of TGF-β1 stimulation on epithelial phenotype marker expression 
A. mRNA expression of epithelial markers 
B. Densitometric analysis of mRNA expression of epithelial markers  
C. Protein expression of epithelial markers 
D. Densitometric analysis of protein expression of epithelial markers  
Figure 4.3. Effect of TGF-β1 stimulation on mesenchymal phenotype marker 
expression 
A. mRNA expression of mesenchymal markers 
B. Densitometric analysis of mRNA expression of mesenchymal markers  
C. Protein expression of mesenchymal markers 
D. Densitometric analysis of protein expression of mesenchymal markers  
Figure 4.4. mRNA expression of multiple phosphodiesterase (PDE) isoforms during 
TGF-β1 induced epithelial mesenchymal transition (EMT) 
A. mRNA expression of PDE isoforms 
B. Densitometric analysis of mRNA expression of PDE isoforms  
Figure 4.5. cAMP-PDE activities during TGF-β1 induced EMT 
Figure 4.6. Protein expression of ERK and P-ERK during TGF-β1 induced EMT. 
A. Protein expression of ERK and P-ERK 
B. Densitometric analysis of protein expression of ERK and P-ERK  
Figure 4.7. Protein expression of PDE4 isoforms during TGF-β1 induced EMT  
A. Protein expression of PDE4 isoforms 
List of figures 
________________________________________________________________________ 
 V 
B. Densitometric analysis of protein expression of PDE4 isoforms 
Figure 4.8. Localization of PDE4 isoforms during TGF-β1 induced EMT  
A. PDE4A localization 
B. PDE4D localization 
Figure 4.9. Analysis of mRNA expression of epithelial and mesenchymal markers in 
PDE4 inhibited TGF-β1 induced EMT 
A. mRNA expression of epithelial and mesenchymal markers 
B. Densitometric analysis of mRNA expression of epithelial markers 
C. Densitometric analysis of mRNA expression of mesenchymal markers 
Figure 4.10. Analysis of protein expression of epithelial and mesenchymal markers in 
PDE4 inhibited TGF-β1 induced EMT 
A. Protein expression of epithelial and mesenchymal markers 
B. Densitometric analysis of mRNA expression of epithelial and 
mesenchymal    markers 
Figure 4.11. Localization of epithelial and mesenchymal markers in PDE4 inhibited 
TGF-β1 induced EMT. 
Figure 4.12. Effect of PDE4 inhibition on TGF-β1 induced Smad signaling  
A. Protein expression of Smad proteins and TRII 
B. Densitometric analysis of protein expression of Smad proteins and TRII  
Figure 4.13. Effect of PDE4 inhibition on ROS production 
Figure 4.14. Effect of ROCK inhibition on TGF-β1 induced EMT 
A. Protein expression of E-Cad and PDE4D 
B. Densitometric analysis of E-Cad and PDE4D 
Figure 5.1. Possible signaling pathway during PDE4 and/or Rho inhibition in TGF-β1 
induced EMT. 
 
 
List of tables 
________________________________________________________________________ 
 VI 
III. List of Tables 
 
Table 1. The EMT proteome 
Table 2. Biochemical characteristics of Human PDE families 
Table 3. List of primers used for PCR amplification 
Table 4. List of primary antibodies  
Table 5. List of secondary antibodies  
 
List of abbreviation 
________________________________________________________________________ 
 VII 
IV. List of abbreviations 
 
AA Amino acid 
AKAP A kinase anchoring protein 
APS Ammonium persulfate 
BSA Bovine serum albumin 
CaM Calmodulin 
cAMP Cyclic adenosine monophosphate 
cDNA Complementary deoxiribonucleic acid 
cGMP Cyclic guanosine monophosphate 
COPD Chronic obstructive pulmonary disease 
Cyt Cytokeratin 
DAPI 4’,6-diamidino-2-phenylindole 
DHE Dihydroergotamine 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO Dimethyl sulfoxide 
DTT Dithiothreitol 
E-Cad E-Cadherin 
EDTA Ethylendinitrilo-N,N,N’ ,N’ tetra acetate 
EGTA Ethylene glycol-bis (2-amino-ethyleter)- N,N,N’ ,N’-tetraacetic acid 
EMT Epithelial to mesenchymal transition 
ERK Extracellular signal-regulated kinases 
FITC Fluorescein-5-isothiocyanate 
FCS Fetal Calf Serum 
FN Fibronectin 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP Horseradish peroxidase 
IB Immunoblotting 
IBMX Isobutylmethylxanthine 
List of abbreviation 
________________________________________________________________________ 
 VIII 
ICCH Immunocytochemistry 
IL Interleukin 
NAC N-acetyl-l-cysteine 
NO Nitric oxide 
PAH Pulmonary arterial hypertension 
PBGD Porphobilinogen deaminase 
PBS Phosphate-buffered saline 
PBST Phosphate-buffered saline + 0,1% Tween 20 
PCR Polymerase chain reaction 
PDE Phosphodiesterase 
PKA  Protein kinase A 
Rho Ras homolog gene family 
ROCK Rho kinase 
ROS Reactive Oxygen Species 
RT-PCR Reverse transcription PCR 
ROCK Rho-associated, coiled-coil containing protein kinase 
SDS Sodium dodecyl sulfate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
SMA Smooth muscle actin 
TAE Tris-acetate EDTA 
TBS Tris Buffered Saline buffer 
TEMED N,N,N',N'-tetramethyl-ethane-1,2-diamine 
TGF Transforming growth factor  
TGF-βRII TGF-β receptor type II 
Summary 
________________________________________________________________________ 
 IX 
V. Summary 
 
Epithelial-mesenchymal transition (EMT) is a series of events in which fully 
differentiated epithelial cells undergo transition to a mesenchymal phenotype giving rise 
to fibroblasts and myofibroblasts. EMT is increasingly recognized as important process 
not only in development, but also in adult life: in wound healing, fibrosis, and the 
invasion and metastasis of tumor cells. The phenotypic conversion involves loss of 
epithelial polarity, loss of epithelial markers, loss of adherens and gap junctions, 
cytoskeletal reorganization, and transition to a spindle-shaped morphology concomitant 
with acquisition of mesenchymal markers and an invasive phenotype. 
Cyclic nucleotide phosphodiesterases (PDE) comprise a family of related 
proteins, which can be subdivided into 11 families (PDE1-PDE11) based on their amino 
acid sequences, sensitivity to different activators and inhibitors and their ability to 
preferentially hydrolyze either cAMP (PDE4, 7, 8) or cGMP (PDE5, 6, 9) or both (PDE1, 
2, 3, 10, 11). cAMP and cGMP are ubiquitous second messengers and consequently 
PDEs propagate many signaling pathways, including proliferation, migration, and 
differentiation. 
The present study was undertaken to evaluate the potential role of 
phosphodiesterases (PDE) in TGF-β1 induced EMT in the human alveolar epithelial 
type-II cell line-A549. TGF-β1 induced EMT was characterized by morphological 
alterations and by expression changes of EMT specific markers. TGF-β1 treatment 
decreased expression of epithelial phenotype markers such as E-cadherin, cytokeratin-18, 
zona occludens-1 and increased expression of mesenchymal phenotype markers such as 
collagen I, fibronectin-EDA and α-smooth muscle actin.  
Interestingly, a 2-fold increase in total cAMP-PDE activity following TGF-β1 stimulation 
was found and attributed to increased PDE3 and PDE4 activities. Further mRNA and 
protein expression demonstrated upregulation of PDE4A and PDE4D isoforms in TGF-
β1 stimulated cells.  
Most importantly, treatment of TGF- β1 stimulated epithelial cells with the PDE4 
selective inhibitor Rolipram potently inhibited EMT changes in a Smad-independent 
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 X 
manner by decreasing reactive oxygen species (ROS). Rolipram pre-treatment resulted in 
E-Cad restoration as well as in Fibronectin abolishement.  
In addition, Rho kinase signaling activated by TGF- β1 during EMT demonstrated as a 
positive regulator of PDE4. Our findings suggest that TGF-β mediated up-regulation of 
PDE4 promotes EMT in alveolar epithelial cells.  
Thus, targeting PDE4 isoforms may be a novel approach to attenuating EMT-associated 
lung diseases, such as pulmonary fibrosis and lung cancer. 
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VI. Zusammenfassung 
Die Epithelial-Mesenchymale Transition (EMT) voll differenzierter Epithelzellen in 
Zellen mesenchymalen Phänotyps, wie (Myo) Fibroblasten, spielt nicht nur beim 
Wachstum und in der Entwicklung eine Rolle, sondern nimmt auch bei Prozessen wie der 
Wundheilung, der Entstehung von Fibrose und der Invasion und Metastasierung von 
Tumorzellen einen wichtigen Stellenwert ein. Während der phänotypischen Umwandlung 
verliert die Zelle, neben ihrer für Epithelzellen typischen Polarität, ihre epithelialen 
Marker und durchläuft eine Neustrukturierung ihres Zellskeletts. Dies hat eine 
spindelförmige Morphologie zur Folge und wird von der Aneignung mesenchymaler 
Marker begleitet. 
Zyklische Nukleotid Phosphodiesterasen (PDEs) bilden eine Familie verwandter 
Proteine, die, basierend auf ihren Aminosäuresequenzen, ihrer Sensitivität gegenüber 
verschiedenen Aktivatoren und Inhibitoren und aufgrund ihrer Fähigkeit entweder cAMP 
oder cGMP oder beide zyklischen Nukleotide zu hydrolisieren, in 11 Familienmitglieder 
eingeteilt werden. Sie beeinflussen mehrere zelluläre Signalwege, sowohl durch den 
Abbau der ubiquitären second messenger cAMP und cGMP, als auch durch direkte 
Interaktion mit anderen Proteinen ,was Auswirkungen auf Proliferation, Migration und 
Differenzierung von Zellen hat. 
In der vorliegenden Arbeit sollte untersucht werden, welche Rolle 
Phosphodiesterasen in der TGF-β1 induzierten EMT von humanen, alveolären Typ II-
Zellen (A549-Zellen) spielen. Die durch die Stimulation mit TGF-β1 induzierte EMT 
wurde anhand morphologischer Veränderungen und durch Genexpressionsanalysen der 
epithelialen Marker E-Cadherin, Zytokeratin-18, Zona Occludens-1 und der 
mesenchymalen Marker Kollagen I, Fibronektin-EDA und α-Smooth Muscle Aktin 
überprüft. Interessanterweise zeigte sich nach der TGF-β1-Stimulation eine 2fach 
gesteigerte Aktivität der cAMP-hydrolysierenden PDEs, welche auf eine erhöhte 
Aktivität der PDEs 3 und 4 zurückgeführt werden konnte. Des Weiteren konnte auf Gen – 
und Proteinexpressionsebene gezeigt werden, dass sowohl die PDE4A, als auch die 
PDE4D in TGF-β1 stimulierten Zellen erhöht exprimiert werden. Zudem ist von 
Bedeutung, dass die Behandlung TGF-β1 stimulierter Zellen mit dem PDE4 spezifischen 
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Inhibitor Rolipram zu einer geringeren Produktion reaktiver Sauerstoffspezies (ROS) 
führte und es so in Smad – unabhängiger Weise zur Epithelial-Mesenchymalen Transition 
kommen konnte. Zusätzlich zeigte sich, dass der Rho-Kinase-Signalweg, welcher 
während der EMT durch TGF-β1 aktiviert wird, einen positiv regulatorischen Effekt auf 
die PDE4 hat. Zusammenfassend weisen unsere Ergebnisse darauf hin, dass die durch 
TGF-β1 verursachte erhöhte Expression der PDE4 die EMT in alveolären Epithelzellen 
begünstigt. Daher wäre eine speziell auf die PDE4 abzielende Behandlung ein neuer 
Ansatz um EMT-assozierte Lungenkrankheiten wie Lungenfibrose und Lungenkrebs zu 
verbessern. 
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 1 
1 Introduction 
1.1 Epithelial to mesenchymal transition 
1.1.1 Characteristic of epithelial to mesenchymal transition 
Epithelial cells cover internal organs and other internal surfaces of the body. 
Major feature of epithelial cells is cell-to-cell contact and monolayers formation. It is 
important during embryonic life for development as well as during adult life for proper 
homeostasis and architecture of epithelium.  
Epithelial cells are polarized and closely adhered by membrane associated 
specialized junctions such as tight junctions, gap junctions, adherens junctions 
(containing E-Cadherin in complexes with β-catenin and α-catenin, linked to the 
cytoskeleton) and desmosomes. In cell culture, epithelial cells grow as clusters that 
maintain complete cell-to-cell adhesion. Specific markers used to describe epithelial 
characteristic include E-Cadherin (E-Cad), zonula ocludens (ZO-1), cytokeratins (cyt), 
apical actin-binding transmembrane protein-1 (MUC-1)1-3. 
E-Cadherin (E-Cad), one of the major epithelial marker and one of the main target during 
EMT, is a calcium dependent adhesion molecule, responsible for morphogenetic 
rearragements and integrity of cells through the formation of adherens junctions. Cells are 
kept close to each other and adhere through the interaction between extracellular domains 
of cadherins. Moreover, also cytoplasmatic tail is required for strong, stable adhesions. 
Cytoplasmic domains have 90-100% similarity, what suggest that that sequences bind 
common adaptors and effectors4.  
E-Cad is able to form complexes with β-catenin and α-catenin. Seronine/threonine 
phosphorylation stabilizes, wheras dephosphorylation disrupts this complex. 
Interestingly, changes in expression and activity of kinases responsible for 
phosphorylation, correlate with changes in cell adhesion and migration4. During EMT, E-
Cad is one of the main targets. When E-Cad level decrease, they can not form complexes 
with β-catenin. As a results, β-catenin localizes from membrane to the nucleus and 
contributes to the Wnt signaling pathway2. 
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Mesenchymal cells do not form layers and are not polarized. They contact each 
other only focally. The only junction they form are gap junctions when passing other 
mesenchymal cells5. In the cell culture they have spindle shape and fibroblast-like 
morphology. Specific markers used to define mesenchymal phenotype are alpha-smooth 
muscle actin (α-SMA), fibronectin (Fn), vimentin, desmin, collagen (coll), the 
transcription factors Snail and Slug and expression of matrix proteinases (MMPs)2 (see 
Table 1). 
Fibronectin is one of the major mesenchymal markers. Fibronectin is an extracellular 
matrix glycoprotein that binds to membrane receptor proteins called integrins. In addition 
to integrins, they also bind extracellular matrix (ECM) components such as collagen or 
fibrin. Fibronectin contributes to the cross-linked network within the ECM, due to its 
binding sites for other ECM components. 
It is already known, that fibronectin is one of the markers gained during TGF-β induced 
epithelial-to-mesenchymal transition6-8.  
Epithelial-to-mesenchymal transition (EMT) is well known mechanism known for 
dispersing cells in verbrate embryos9, forming fibroblasts in injured tissues10 or intiating 
metastases in epithelial cancer11,12 (see Figure 1.1). 
During EMT epithelial cells are disaggregated and reshaped for movement. Cells lose 
polarity, adherens and tight junctions, desmosomes and cytokeratin intermediate 
filaments. They became highly motile and migrate what is the effect of rearrangement of 
the cytoskeleton and formation of new cell-subtratum contacts, and allow them to pass 
through the underlying basement membrane. 
 
Table 1. The EMT proteome13 
Proteins gained or maintained Proteins attenuated 
Snail, Slug, Scratch, SIP1, E47, Ets, FTS 
binding protein, RhoB, FSP1, TGF- β, 
FGF-1,2,8, MMP-2,9, vimentin, α-SMA, 
Fibronectin, Collagen type I, III, 
Thrombospondin, PAI-1 
E-Cadherin, ZO-1, β-catenin, Despoplakin, 
Muc-1, Syndecan-1, Cytokeratin-18 
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Figure 1.1. Basic mechanisms of epithelial-to-mesenchymal transition (EMT). 
 
1.1.2 Induction of EMT 
EMT can be triggered either by oncogenic activation either by specific growth 
factors (such as transforming growth factor β, TGF-β; fibroblast growth factor, FGF; 
epidermal growth factor, EGF; insulin-like growth factor, IGF; hepatocyte growth factor, 
HGF; connective tissue growth factor, CTGF; interleukin-1, IL-1) or by extracellular 
matrix components (for example collagen or hyaluronic acid)2,3.  
 
 
1.1.3 TGF-β and its role during EMT 
It is already known that TGF-β is a major inducer of EMT in development, 
carcinogenesis and fibrosis5. Disturbance of TGF-β signaling pathway has been 
implicated in several developmental disorders and in various human diseases14. 
The first notes about TGF-β as a inducer of EMT, came from experiments with normal 
mammary epithelial cells15. Since that time, its effect was shown in a number of different 
epithelial cells. 
Epithelial cells 
-tight junctions 
-adherence junctions 
-cell-to-cell contact 
EMT EMT 
Mesenchymal cells 
-focal contact 
-elongated and spindle shaped 
-cytoskeleton reorganization 
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effectors: 
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TGF-β is multifunctional cytokine that regulates tissue morphogenesis and 
differentiation through effects on cell proliferation, differentiation, apoptosis and 
extracellular matrix production1.  
TGF-β1 exerts its effects by binding to the TGF-β type II receptor (TβRII) and 
subsequently recruiting the TGF-β type I receptor (TβRI). Smad 2/3 and Smad 4 are 
known intracellular mediators of TGF-β1. Once phosphorylated by the activated TGF-β1 
receptor, Smad 2 and/or Smad 3 complex with Smad 4 and translocate to the nucleus 
where they regulate TGF-β1 target genes16,17,18. 
On the other hand, TGF-β1 can also regulate its target genes via Non-Smad-dependent 
pathways that include the RhoA, Ras, MAPK, PI3 kinase, Notch, and Wnt signaling 
pathways19,20,21. 
 
Figure 1.2.  Transforming growth factor β1 (TGF- β1) signaling pathway. Adapted 
from Cambridge University Press 2003. 
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1.1.4 EMT in embryo and adults 
 
1.1.4.1 EMT in development 
During embryogenesis, a number of extracellular signals can trigger the 
conversion of epithelial cells into mesenchymal cells by triggering EMT. Mesenchymal 
cells do not derive exclusively from the mesoderm primary germ layer, but they can be 
produced by epithelial endodermal cells2. 
Mesenchymal cells allow the shaping of the embryo during gastrulation. They are also 
able to move and settle at sites of critical epithelial–mesenchymal interactions or they can 
differentiate into new structures2. 
 
 
1.1.4.2 EMT in wound healing 
 Epithelial cells and fibroblasts are major regulatory elements of epithelialization 
and wound contraction. Fibroblasts contribute to contraction directly by producing 
contractile forces and indirectly via differentiating into mesenchymal cells such as 
myofibroblasts. The epithelium, once considered to be terminally differentiated, has the 
ability to differentiate into mesenchymal cells and the occurrence of EMT following 
epithelial stress such as inflammation or wound has been documented10,22. 
 
 
1.1.4.3 EMT in cancer  
In order to develop cancer, tumour cells must be invasive and migrate from 
primary tumour sites into the surrounding tissue. To be able to do so, tumour cells 
undergo some phenotypic changes and it is believed that this happen during EMT. Recent 
studies indicated that EMT is indeed involved in tumour progression. 
Tumour cells that gained mesenchymal characteristics such as enhance motility or 
activation of proteolysis, are able to metastasize and establish secondary tumours at 
distant sites2. It was also demonstrated that manipulation in E-Cad expression causes the 
effects on phenotype and invasive properties. It was shown that loss of E-Cad expression 
and function can be observed in most of carcinomas, and was proposed that this gene can 
be a invasion suppressor gene during EMT23. 
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1.1.4.4 EMT in fibrosis 
The molecular basis of EMT with respect to fibrosis is starting to emerge as it is 
believed that inflammatory mediators that are produced in response to injury cause EMT, 
which can lead to fibrosis2.  
TGFβ levels are increased in the lungs of patients with fibrotic pulmonary diseases such 
as idiopathic pulmonary fibrosis. TGFβ induces EMT of alveolar epithelial cells and 
fibroblastic cells that express both epithelial and mesenchymal markers can be detected in 
human biopsies. Furthermore, a significant body of evidence points to TGFβ-induced 
EMT of lens epithelial cells as an important event during cataract formation and injury-
induced lens-capsule fibrosis2.  
EMT has also been demonstrated in the fibrosis of various other organs including the 
lung, liver, anterior sub capsular cataracts in humans1,10,24. 
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1.2 Phosphodiesterases 
1.2.1 Nomenclature of Phosphodiesterases 
Cyclic nucleotide phosphodiesterases are the enzymes which effectively catalyze 
the hydrolysis of cAMP and/or cGMP. 
PDEs are classified into I, II or III class. Mammalian PDEs belong to class I. 
There have been identified twenty-one genes encoding PDEs in human genome and more 
then 50 different isoforms of PDEs, and they have been classified into 11 families (PDE1 
– 11) according to the genes of which they are products, their biochemical properties, 
regulation and sensivity to pharmacological agents 25.  
According to the nomenclature used for each PDE isozyme (eg. HSPDE4D), the first two 
letters indicate the animal species, the first Arabic number after PDE indicates PDE gene 
family, following a single capital letter indicates a distinct subfamily gene and the last 
Arabic number indicates a specific splice variant or a specific transcript generated from a 
unique transcription initiation site (http://depts.washington.edu/pde/pde.html). 
 
 
1.2.2 Classification of Phosphodiesterases 
Among the multiple isoforms of phosphodiesterases, the enzymes belonging to 
three families (PDE4, 7, 8) are belived to be only cyclic AMP specific, three families 
(PDE5, 6, 9) are cyclic GMP specific and five families (PDE1, 2, 3, 10, 11) display dual 
substrate specifity. 
 
 
1.2.2.1 cGMP 
Cyclic guanosine monophosphate (cGMP) is a cyclic nucleotide synthesized by 
soluble or particulate guanylate cyclases (GC) from guanosine triphosphate (GTP), 
wheras hydrolyzed to guanosine monophosphate (GMP) by PDEs (Figure 1.3.). 
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cGMP acts as a second messenger mostly by activating intracellular protein kinases, for 
example PKG. cGMP is known to be a common regulator of ion channel conductance, 
glycogenolysis, and cellular apoptosis. It also plays a role in smooth muscle relaxation 
and migration26,27. 
 
 
Figure 1.3. Synthesis and hydrolysis of cGMP. GC – guanylate cyclase, PDE – 
phosphodiesterase. 
 
 
1.2.2.2 cAMP 
Cyclic adenosine monophosphate (cAMP) is a cyclic nucleotide synthesized by 
adenylyl cyclases (AC) from adenosine triphosphate (ATP), wheras hydrolyzed to 
adenosine monophosphate (AMP) by PDEs (Figure 1.4) 
Cyclic AMP mainly activates protein kinase A (PKA). PKA is a holoenzyme composed 
of two genetically distinct regulatory (R) and two catalytic (C) subunits that form a 
tetrameric holoenzyme (R2C2). In the absence of cAMP, PKA exists as a stable inactive 
tetramer; the catalytic activity of cAMP is suppressed when the C subunits form a 
complex with the R subunits. After an increase in intracellular cAMP, the regulatory 
PKA subunits bind to cAMP, which results in the disassociation of the holoenzyme into 
an R2(cAMP)4 dimer and two monomers of catalytically active C kinase. The R subunits 
remain in the cytoplasm, and the free catalytic subunits either translocate into the nucleus 
or remain in the cytosol. In both locations, PKA C subunits phosphorylate serine and 
threonine residues of specific substrates. In the nucleus, regulation of transcription by 
PKA is mediated by cAMP-responsive nuclear factors, which bind to and regulate the 
expression of genes containing a cAMP-response element binding element (CRE) 
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consensus in their promoter region. Phosphorylation of the CRE binding protein (CREB) 
modulates its activity28. 
 
 
Figure 1.4. Synthesis and hydrolysis of cGMP. AC – adenylate cyclase, PDE – 
phosphodiesterase 
 
 
 
 
Figure 1.5. AC-cAMP-PKA signaling pathway. Adapted from Dwivedi et al. 2008 
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1.2.3 Structure of Phosphodiesterases 
Phosphodiesterases contain three functional domains: conserved catalytic domain, 
a regulatory N-terminus domain and C-terminus domain.  
Catalytic domain (approximately 270 amino acids) constitutes the core of PDE and is a 
higly conserved region, with a 20 – 45% identity. It contains consensus metal binding 
domains: 2 Zn2+ binding motifs and a Mg2+ binding motif related to metal-ion 
phosphohydrolases 29 . The putative role of this ions include stabilization of the structure 
and activation of hydroxide to mediate catalysis.  
Regulatory domains are placed between the amino terminus and the catalytic domain on 
which are located calmodulin binding sites for PDE1, allosteric cGMP binding sites 
(GAF domains for PDE2, 5, 6, 10, 11), phosphorylation sites, phosphatidic binding site 
for PDE4, PAS domain for PDE8, autoinhibitory sequences for PDE1 and PDE4, 
membrane association domain for PDE2 - 4, dimerization motifs30,31 . 
 
 
1.2.4 Cyclic nucleotide recognition and hydrolysis 
It is known from structural studies that the cyclic nucleotide specifity of the 
catalytic site depends largely on one particular invariant glutamine. The idea is that this 
glutamine stabilizes the banding of the purine ring in the binding pocket through 
hydrogen bonds that form with cAMP or cGMP or both, depending on the orientation of 
the glutamine. Freely rotation of this glutamine is required for efficient binding of cyclic 
nucleotides. If the rotation is blocked by some neighboring residues, the preferred 
substrate will be either cAMP or cGMP, but not both. For the PDEs that show very high 
selectivity, the rotation hindered32. 
 
1.2.5 Biochemical characteristics and structure of Human PDE 
Families 
A complete overview of the PDE isoforms, substrate specificity, relevance and 
localization is given in Table 233,34. 
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Table 2. Biochemical characteristics of Human PDE families 
Isoforms Substrate 
specificity 
Relevance Tissue/Cellular 
localization 
Intracellular localization 
PDE1A 
 
PDE1B 
 
PDE1C 
cAMP<cGMP 
 
cAMP<cGMP 
 
cAMP=cGMP 
Calcium/ 
calmodulin 
regulated 
SMC,heart,lung,brain,sperm 
Neurons,lymphocytes, 
macrophages, SMC 
 
Brain,SMC,sperm, 
epithelium 
Mostly cytosolic 
 
Cytosolic 
 
 
Cytosolic 
PDE2A cAMP=cGMP cGMP 
stimulated 
Brain,naurons,heart,platelet,
macrophage, endothelium 
PDE2A1 cytosolic, 
PDE2A2 and PDE2A3 
membrane 
PDE3A 
 
 
PDE3B 
cAMP>cGMP 
 
 
cAMP>cGMP 
cGMP inhibited Heart,SMC,platelet,oocyte, 
kidney, cardiovascular 
tissues 
SMC,adipocytes, kidney 
hepatocytes,β cells,sperm,T 
lymphocytes, macrophages 
Membrane/ 
Cytosolic 
 
Membrane 
PDE4A 
 
 
 
PDE4B 
PDE4C 
 
PDE4D 
cAMP 
 
 
 
cAMP 
cAMP 
 
cAMP 
cAMP specific, 
Rolipram 
sensitive 
Immune cells,testis,brain, 
olfactory system 
 
 
Immune cells,brain 
Lung,testis,neuronal origin 
cell lines 
Variety of tissues, 
commonly used cell lines 
and inflammatory cells 
Membrane/interaction 
with Src kinases or β-
arrestin  
 
Interaction with β-arrestin 
Cytosolic 
 
Cytosolic/particulate 
PDE5A cGMP cGMP binding, 
cGMP specific 
SMC,brain,lung,heart, 
kidney,skeletal muscle 
Cytosolic 
PDE6A 
PDE6B 
PDE6C 
cGMP 
cGMP 
cGMP 
Photoreceptor Rod cells,pineal gland 
Rod cells,pineal gland 
Cone cells,pineal gland 
Association with δ 
subunit 
PDE7A 
 
PDE7B 
cAMP 
 
cAMP 
Rolipram 
insensitive 
Immune cells, heart, skeletal 
muscle, endothelium 
Brain,heart,liver, testis, 
skeletal muscle, pancreas, 
Cytosolic 
 
Cytosolic 
PDE8A 
 
PDE8B 
cAMP 
 
cAMP 
cAMP specific Testis,spleen,ovary, colon, 
kidney 
Brain,thyroid 
Cytosolic/particulate 
PDE9A cGMP cGMP specific, 
IBMX 
insensitive 
Nearly every tissue, mostly 
kidney,brain, spleen, 
prostate 
PDE9A5 cytosolic; 
PDE9A1 nucleus 
PDE10A cAMP>cGMP cAMP inhibited Brain,testis,heart,thyroid,car
diac muscle,pituitary gland 
PDE10A1 and 10A3 
cytosolic; PDE10A2 
particulate 
PDE11A cAMP>cGMP Dual substrate Skeletal muscle,prostate, 
testis, salivary gland,thyroid 
gland,liver 
Cytosolic 
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1.2.6 Phospodiesterase 4 family 
1.2.6.1 General structure 
The PDE4 family are a cAMP-specific, rolipram-sensitive phosphodiesterases, 
encoded by four genes (PDE4A, 4B, 4C, 4D). These four genes are able to generate more 
then twenty different variants by means of alternative start sites and alternative splicing33. 
These splicing variants are divided according to N-terminal variant into three goups: so 
called “long-form” (presence of N-terminal “upstream conserved regions”, UCR), “short-
form” and “super short-form” (absence of N-terminal “upstream conserved regions”). All 
of the “long-forms” contains UCR1, linker region (LR) 1, UCR2, LR2 and the catalytic 
domain. The “short-form” lack UCR1 and “super short-form” lack UCR1 and contain 
truncated ULR2. 
UCR1 (formed from ~60 aminoacids) comprises one PKA phosphorylation site, and 
UCR2 (forms from some ~80 aminoacids) a hydrophilic N-terminal region which interact 
with the hydrophobic C-terminal part of UCR1. Moreover, UCR1 and UCR2 are 
involved in enzymatic regulation, particulary in integrating the effect of 
phosphorylation32.The catalytic domain is rather conserved and it shows around 75% 
sequence identity among all PDE4 members.  
 
 
Figure 1.6. PDE4 family structure. 
 
Catalytic domain UCR2 UCR1 
Catalytic domain UCR2 
truncated 
UCR2 Catalytic domain 
Long form: 
4A4/5, 8, 10, 11 
4B1, 3, 4 
4C1, 2, 3 
4D3, 4, 5, 7, 8, 9 
Short form: 
4B2 
4D1, 2 
Super-short form: 
4A1 
4B5 
4D6 
COOH 
COOH 
COOH H2N 
H2N 
H2N 
LR LR
LR
LR
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1.2.6.2 PDE4 interactions 
PDE4 family can actively control and regulate level of cAMP through interactions 
with other proteins, such like A kinase anchoring protein (AKAP), arrestins, tyrosine 
kinases and receptor for activated protein C (RACK1). 
 
1. A kinase-anchoring proteins (AKAPs) 
Most interactions with kinases and phosphatases are mediated by proteins called A 
kinase-anchoring proteins (AKAPs). AKAPs are a family of more then 50 anchoring 
proteins which have ability to create complexes with target signal-termination enzymes 
such as phosphatases, kinases (PKA, PKC) and phospohodiesterases, and then anchor this 
complexes in specific subcellular domains. Through this they are able to regulate specific 
signaling pathways32,35. 
It has been shown that PDE4D forms complex with PKA subunit and mAKAP in rat 
heart extracts36.Moreover, it has been shown that PDE4D3 directly interacts with 
mAKAP and that is co-localizes with mAKAP at the nuclear membrane of 
cardiomiocytes36. Though, there is a possibility that if PDE4D3 and PKA are associated 
with mAKAP, and regulate local cAMP level as well as PKA activity. 
Additionally, the experiments with PDE4D null mice were performed. Absence of 
PDE4D from complex involving PKA, mAKAP and ryanodine receptor, causes 
constitutive phosphorylation of this channel37.  
It was shown that PDE4D3 together with mAKAP and PKA, can form complex with 
Epac (exchange protein activated by cAMP) and MAPK5. Through this complex, 
PDE4D3 is regulated by MAPK and is thought to play a role in cardiac hypertrophy38. 
 
2. Arrestins 
PKA phosphorylates β2-adrenoreceptor (β2AR), what switches its predominant coupling 
from stimulatory guanine nucleotide regulatory protein (Gs) to inhibitory guanine 
nucleotide regulatory protein (Gi). Catalytic site of PDE4s binds to mediatory β-
arrestin1/2 and this complex is recruited to the β2AR, can degrade cAMP and through this 
PKA activity at the membrane can be controlled39. 
It has been also proposed that PDE4/arrestin complex plays a role in regulation of 
signaling from the T cell receptor during lymphocyte activation40. 
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3. Tyrosine kinases (Src, Lyn, Fyn) 
N-terminal regions of PDE4A4/5 and PDE4D4 comprise proline-containing motifs, 
which are able to interact with SH3 domains of protein-tyrosine kinases, such as Src, 
Lyn, Fyn. 
This interaction can have influence on the specificity as well as localization of PDE4A/D. 
For example, human PDE4A5 contain additional site for reaction with SH3 domains. 
This site is located in LR2 (see Rys.1 PDE structure) which is encoded by single exon. 
Moreover, this exon encodes an insertion of a ten aminoacids sequence (rich in proline 
and arginine). When Lyn and Src bind to this site, sensitivity  of PDE4A to inhibition by 
rolipram is significantly enhanced41. 
Additionaly, PDE4A5 is associated with cell membrane and is localized at the cell 
periphery and is bound to ruffles. It was shown that when site for interaction with SH3 
domain is deleted or disrupted, prevents this interaction and allows it to be distributed 
equally through the cell margin42. 
 
4. Receptor for activated C kinase 1 (RACK1) 
PDE4D5 contain on N-terminal region domain called RAID1 (RACK1 interaction 
domain) through which can bind to RACK1. RACK1 is a signaling protein formed from 
seven tryptophan-aspartate repeats that binds to PKC isoforms. RAID1 contain 
hydrophobic amino acids, and reacts with a site on RACK1 that is formed primarily from 
tryptophan-aspartate. However, the functional role of this interaction is not known, 
because it does not change PDE4D5 activity, but it does change a little sensivity to 
inhibition by rolipram. The probable role may be that recruitment of PDE4D5 by RACK1 
to signaling complex, modulates and controls cAMP levels and through this regulates  
PKA phosphorylation of RACK1-associated proteins43,44. 
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1.2.6.3 PDE4 regulation 
Recent studies show that phosphorylation plays an important role for PDE4 
activation. 
PKA phosphorylates serine residue in UCR1 at the N-terminal end of PDE4, and though 
activates long PDE4 isoforms45,46. It is believed that PKA phosphorylation in UCR1 
causing disruption of interaction between UCR1 and UCR2 through conformational 
changes47. 
It has been shown that PKA activation can be mimicked when serine residues was 
replaced by aspartate or glutamate residue. Moreover, it was also observed that this target 
serine is next to glutamate residue residue that is conserved in all PDE4 subfamilies and 
which attenuates phosphorylation by PKA. Mutation of this glutamate residues to a 
neutral amino acid also mimics activation by PKA phosphorylation 44,48.  
Moreover, mutation of Ser54 in UCR1 to aspartic acid which also mimics PKA-
dependent activation, reduced the interaction between UCR1 and UCR247. Concerning 
this idea, it was also shown that PKA phopshorylation additionally increases the 
sensitivity of PDE4D3 and PDE4A4 to stimulation by Mg2+ that is found in catalytic 
domain and is essential for PDE activity46. 
On the other side, ERK (Extracellular Signal-regulated Kinase) regulates PDE4 activity 
via phosphorylation, causing inhibition as well as activation of PDE4.  
All PDE4 subfamilies, except PDE4A, contain in a catalytic domain a single ERK 
consensus motif (Pro-Xaa-Ser-Pro). It is already known in vitro and in vivo that serine 
from this motif can be phosphorylated by ERK49,50.  
Moreover, phosphorylation of Ser579 by ERK2, inhibits PDE4D3 and through this 
probably modulate cAMP signaling. This effect could be mimicked by the Ser579 → Asp 
mutant form of PDE4D349-51. In comparison, mutation of Ser579 → Ala  ablated the 
ability of ERK2 to be co-immunoprecipitated with PDE4D3 and abolished the ERK2-
mediated inhibition of PDE4D350. In comparison, PDE4D1 has been shown to be 
activated by ERK2. 
It was also demonstrated that PDE4B and PDE4C share an identical motif to that found 
in members of the PDE4D family51. Long form of PDE4B and PDE4C can be 
phosphorylated by ERK2 and this inhibits its activity, wheras activates PDE4B249. 
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It is believed that UCR1 and UCR2 regions interact with each other and form a segment 
which can regulate the activity of catalytic unit47. Proposed model of this interaction 
shows that  between carboxyl-terminal group of UCR1 and amino-terminal group of 
UCR2 communication occurs. Moreover, mutation of Ser54 → Asp or Ser54 → Ala in 
the UCR1, abolished UCR1–UCR2 interaction, wheras mutation of Ser54 → Thr or 
Glu53 → Ala did not block this interaction. Therefore, it is possible that Ser54 is 
essential for UCR1-UCR2 interaction. It was also observed that this interaction is PKA-
depentent since this enzyme can phosphorylate Ser54. Such a phosphorylation prevents 
UCR1 region from reacting with UCR247.  
 
1.2.6.4 PDE4 inhibitors 
Rolipram (4-(3-cyclopentyloxy-4-methoxy-phenyl)pyrrolidin-2-one) is the first 
and prototype PDE4 inhibitor. It was developed as a anti-depressant drug by Schering 
AG.  
According to accepted idea, catalytic domain of PDE4 can exist in at least two 
conformational states. This states differ between each other depending on the affinity to 
rolipram. “LARBS” is a “low-affinity-rolipram-binding-site” with IC50 in the range of 
0,1-1.0 µM and “HARBS” is a “high-affinity-rolipram-binding-site” with with IC50 in the 
range 1-50nM. Rolipram has been found to bind to HARBS, distinct from the catalytic 
site.  
High- and low-affinity rolipram binding is up to single site which can be in two 
conformational different forms. Switching between this states depends on modifications, 
such as interaction with other proteins and phosphorylation.  
It was shown that the concentration of Mg2+ has ability to modify this states of enzyme. 
PDE4 conformations are the consequence of PDE4 binding to Mg2+- its metal cofactor. 
Mg2+ -deficient enzyme is inactive and has low affinity for rolipram52.  
It was also demonstrated that Mg2+ binding is upregulated by phosphorylation of serine. 
A partially phosphorylated PDE4D3 shown much lower rolipram affinity state in 
compare to fully phosphorylated Ser54 and in consequence increased catalytic potency 
for rolipram52. 
It was also proposed that inhibitor selectivity is determined by a combination of different 
amino acids and subtle conformational changes at the active site of each PDE family53. 
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PDE inhibitors are currently known in therapeutical use and particular PDE4 inhibitors 
have proven as potential drugs, for example in asthma, COPD, rhinitis, arthritis, psoriais, 
depression. In recent years, new generation of PDE4 inhibitors have been developed as an 
attempt to improve the therapeutic index of the first generation of PDE4 inhibitors such 
as rolipram. New generation of such a inhibitors include roflumilast (Daxas) and 
cilomilast that are currently in phase III trials for treatment of COPD.  
Moreover, in animal models treatment with rolipram seems to enhance several models of 
learning and memory33. 
 
Figure 1.7. Structure of Rolipram  
 
Aim of the study 
________________________________________________________________________ 
 18 
2 Aim of the study 
 
It is well known that dysregulation of PDE isoforms may contribute to the 
development of several pulmonary diseases, such as pulmonary hypertension (PAH), 
chronic obstructive pulmonary disease (COPD) or asthma. 
On the other hand, EMT is a process whereby fully differentiated epithelial cells undergo 
transition to a mesenchymal phenotype giving rise to fibroblasts and myofibroblasts, and 
is recognized as an important process not only in development, but also in wound 
healing, fibrosis, as well as in invasion and metastasis of tumor cells. 
However, until now the direct involvement of PDE family members and therapeutic value 
of PDE specific inhibitors in the process of EMT has not been reported in detail. 
 
In this context, the research focus was: 
1. to ascertain the expression pattern of PDE isoforms upon TGF-β1 induced EMT 
of A549 cells;  
2. to investigate whether altered PDE expression has a functional effect on cAMP 
accumulation and differentiation of A549 cells using PDE isoform specific 
inhibitors;  
3. to elucidate the signaling pathways in the PDE-mediated regulation of EMT.  
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3. Materials and methods 
3.1. Materials  
3.1.1. Equipment 
Name  Company 
Cell Culture Incubator, Hera Cell Heraeus, Germany 
Chromatography Columns Bio-Rad, USA 
Electrophoresis Chambers Biometra, Germany 
Falcon Tubes Greiner Bio-One, Germany 
Film Casette Kodak, USA 
Filter Tips: 10; 100; 1000µl Eppendorf, Germany 
Fluorescence Microscope, LEICA Leica, Germany 
Frezer -80˚C Bosh, Germany 
Freezer -20˚C Bosch, Germany 
Freezer +4˚C Bosch, Germany 
Gel Blotting Paper Bio-Rad, USA 
Glass Bottles: 0,1; 0,2; 1l  Schott Duran, Germany 
Glass Pipetes Greiner Bio-One, Germany 
Light Microscope Hund, Germany 
Multifuge Centrifuge Heraeus, Germany 
NanoDrop  PeqLab, Germany 
PCR-thermocycler Biometria, Germany 
Petri Dish Greiner Bio-One, Germany 
Pipetboy Eppendorf, Germany 
Pipets Eppendorf, Germany 
Power Supply Biometria, Germany 
Radiographic Film Hypersensitive Amersham Bioscences, UK 
Radiographic Film Kodak Kodak, USA 
Serological pipette: 5, 10, 25, 50 ml BD Falcon, USA 
Tissue Culture Chamber Slides BD Falcon, USA 
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Tissue Culture Dish 100mm Greiner Bio-One, Germany 
Tissue Culture Flask 250mm Greiner Bio-One, Germany 
Tissue Culture 6well Plate Greiner Bio-One, Germany 
Transilluminator BioDocAnalyzer Biometria, Germany 
Water Bath for Cell Culture Medingen, Germany 
Western Blot Chambers  Biometra, Germany 
Vortex Machine VWR, Germany 
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3.1.2. Reagents 
 
Product Name Company 
Ammonium persulfate Sigma-Aldrich, Germany 
1-Butanol (n-butyl alcohol) Merck, Germany 
2-Mercapto-ethanol Sigma-Aldrich, Germany 
2-Propanol Fluka, Germany 
Acetic Acid, Glacial 99+% Sigma-Aldrich, Germany 
Acetone 99,5+% A.C.S. reagent Sigma-Aldrich, Germany 
Acrylamide solution, Rotiphorese gel 30 Roth, Germany 
Agarose Fluka, Germany 
Albumine, Bovine serum Sigma-Aldrich, Germany 
Ammonium Acetate Sigma-Aldrich, Germany 
Ammonium formate Sigma-Aldrich, Germany 
Brillant Blue G Sigma-Aldrich, Germany 
Calcium Chloride Sigma-Aldrich, Germany 
DMEM-F12 medium  Gibco BRL, Germany 
Dimethyl Sulfoxide Sigma-Aldrich, Germany 
DNA Ladder (100bp, 1kb) Promega, USA 
Dulbecco’s phosphate buffered saline 1x PAN, Germany 
Ethanol absolut Riedel-de Haen, Germany 
Ethidium Bromide Sigma-Aldrich, Germany 
Ethylene glycol-bis(ß-amino-ethylether)-
N,N,N',N'tetraacetic acid (EGTA) Sigma-Aldrich, Germany 
Ethylenediamine-Tetraacetic acid (EDTA) Sigma-Aldrich, Germany 
ECL Plus Western Blotting Detection System  Amersham Biosciences 
Fetal Calf Serum (FCS) Biowest, USA 
Formaldehyde Sigma-Aldrich, Germany 
Glycerol Sigma-Aldrich, Germany 
Glycine, minimum 99% TLC Sigma-Aldrich, Germany 
GoTaq ® Flexi DNA polymerase Promega, USA 
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2-(-4-2-hydroxyethyl)-piperazinyl-1-ethansulfonate 
(HEPES) Sigma-Aldrich, Germany 
Hydrochloric Acid  Sigma-Aldrich, Germany 
ImProm-IITM Reverse Transcriptase  Promega, USA 
Magnesium chloride (anhydrous) Sigma-Aldrich, Germany 
Methanol Fluka, Germany 
Milk Powder Roth, Germany 
N,N,N',N'-Tetramethyl-1-,2-diaminomethane (TEMED) Sigma-Aldrich, Germany 
N,N’-Methylene-bis-Acrylamide Sigma-Aldrich, Germany 
Oligo(dT) Primer  Promega, USA 
Penicillin-Streptomycin PAA Laboratories, Austria 
PCR Nucleotide Mix Promega, USA 
Ponceau S Solution Sigma-Aldrich, Germany 
Potassium hydroxide, Sigma Ultra Sigma-Aldrich, Germany 
Potassium Phosphate monobasic Sigma-Aldrich, Germany 
QAE Sephadex Amersham Biosciences 
RNase Away Molecular Bioproducts 
RNAsin inhibitor   Promega, USA 
RIPA buffer Santa Cruz, Germany 
SDS Solution, 10% w/v Promega, USA 
Sodium Chloride Riedel-de Haen, Germany 
Sodium citrate tribasic dihydrate Sigma-Aldrich, Germany 
Sodium hydroxide Sigma-Aldrich, Germany 
Sodium Phosphate (monobasic, anhydrous) Sigma-Aldrich, Germany 
Tris-HCl 1M  Sigma-Aldrich, Germany 
Trizma base, minimum 99.9% titration Sigma-Aldrich, Germany 
Trypsin/EDTA PAA Laboratories, Austria 
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3.2. Methods 
3.2.1. RNA isolation 
Total RNA was isolated from the cells using TRIzol™ reagent. Cells were 
resuspended in 1,0ml of TRIzol™ reagent and incubated for 10min in room temperature. 
After adding 200µl of chloroform, vortexing for 15sec and incubating in room 
temperature for 10min, samples were centrifuged for 25min (4˚C, 13000xg). After 
centrifugation aqueous phase was transferred to new tube and 0,5ml isopropanol per 
1,0ml of TRIzol reagent used was added for precipitation of RNA. Probes were incubated 
in room temperature for 10min and then centrifuged for 10min (4˚C, 13000xg). Pellet 
was washed with 0,5ml of 75% ethanol per 1,0ml of TRIzol reagent used and centrifuged 
for 10min (4˚C, 13000xg). The RNA pellet was redissolved in DEPC treated water, 
warmed for 10min in 55˚C and stored in -80˚C.  
RNA purity and concentration were measured spectroscopically by its absorbance in 
260nm and 280nm in NanoDrop. 
 
3.2.2. Reverse transcriptase reaction 
Reverse transcriptase reaction (RT) is an enzymatic technique for amplifying a 
defined piece of a RNA into complementary DNA (cDNA) by an enzyme reverse 
transcriptase. 
cDNA was synthesized from total RNA using ImpromII Reverse Transcriptase Kit. 3µg 
of RNA was used per single reaction. cDNA synthesis was performed in 2 steps. In first 
step RNA was mixed with 1µl oligo(dT) (100µg/ml) and the nuclease free water till the 
final volume of 5µl. The reaction mixture was heated to 70˚C for 5min.  
In the second step RT mixture was added as follows: 
RT reaction component Volume Final concentration 
5xRT buffer 4µl 1x 
25mM MgCl2 4,8µl 6mM 
10mM dNTP mix 1µl 0,5mM 
RNAsin inhibitor (1U/µl) 1µl 1U 
Reverse transcriptase (1U/µl) 1µl 1U 
H2O (RNase free) 3,2µl - 
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The reaction mixture was vortexed, spined down and kept at 25˚C for 5min and then at 
42˚C for 1h. Synthesized cRNA was used for PCR or stored in -20˚C. 
 
3.2.3. Polymerase chain reaction 
Polymerase chain reaction (PCR) is an enzymatic technique used to amplify 
cDNA by an enzyme DNA polymerase. Each PCR cycle contain 3 steps: denaturation 
(separation of double stranded cDNA into single stranded); annealing (primers binding to 
specific sites in single stranded cDNA) and elongation (synthesis of new DNA by DNA 
polymerase). 
PCR was performed on cDNA prepared as described in (3.2.2) using GoTaq® Flex DNA 
Polymerase Kit (Promega). 
 
 PCR reaction Mix was added as follows: 
PCR reaction component Volume Final concentration 
5xPCR buffer 10µl 1x 
25mM MgCl2 5µl 2,5mM 
10mM dNTP mix 1µl 0,2mM 
10µM of forward primer* 1µl 0,2µM 
10µM of reverse primer* 1µl 0,2µM 
Taq DNA polymerase (5U/ml) 0,25µl 1,25U 
cDNA 1µl - 
H2O (nuclease free) 5,75µl - 
 
PCR components were mixed on ice, vortexed, spined down and placed in the Thermal 
Cycler. Number of cycles depend on the amplified sequence.  
Programmed steps were as follows: 
Step Time Temperature 
Denaturation 30s 94˚C 
Annealing 30s Variable* 
Elongation 1min 72˚C 
Final elongation 5min 72˚C 
 
*Primers seguences and annealing temperature are listed in Appendix in Table 3. 
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3.2.4. Agarose gel electrophoresis 
DNA agarose gel electrophoresis was performed to visualize and analyze PCR 
products. The preparation of 1% gel was as follows: agarose was mixed with 1xTAE 
buffer and ethidium bromide (1µg/ml). PCR products and GeneRuler DNA ladder were 
loaded and the gel was run in 1xTAE buffer at 80V.  
DNA bands were visualized under UV-transilluminator of Biometra system. 
 
1xTAE Buffer 
40mM Tris-acetate, pH=8,0 
1mM EDTA, pH=8,0 
 
3.2.5. Protein isolation  
Harvested cells were lysed in RIPA buffer containing DMSO, protease inhibitor 
and PMSF. Lysates were incubated on ice for 30min and then subjected to a low-speed 
centrifugation (13000xg for 30 min). Supernatants were placed in new tubes and stored in         
-80˚C.  
 
3.2.6. Protein quantification 
Protein quantification was performed using Quick Start™ Bradford Dye Reagent 
(Biorad). The Bradford assay is determination method that involved the binding of 
Coomassie Brilliant Blue G-250 dye to proteins. When the dye binds to protein it is 
converted to a stable blue form. This form is detected at 595nm using a 
spectrophotometer reader. BSA in different concentration was used as a standard. 
 
3.2.7. SDS polyacrylamide gel electrophoresis 
SDS polyacrylamide gel electrophoresis was performed to separate proteins 
according to its size. Before loading, proteins were mixed with 5x SDS-loading buffer 
and denaturated by heating in 100˚C for 10min. This prepared mix was loaded into the 
SDS acrylamide gel (consists of 10% resolving gel and 5% stacking gel) and run in SDS-
running buffer at 130V.  
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SDS-running buffer 
25mM Tris 
250mM Glycine 
0,1% (w/v) SDS 
 
5xSDS-loading buffer 
0,25mol/l Tris-HCl, pH=6,8 
10% (w/v) SDS 
50% Glycerol 
0,5mol/l DTT 
0,5% Bromophenol Blue 
 
Stacking gel (5%) 
5% acrylamide:bisacrylamide  
125mM Tris-HCl, pH=6,8 
0,1% (w/v) SDS 
0,1% (w/v) APS 
0,1% (v/v) TEMED 
 
Resolving gel (10%) 
10% acrylamide:bisacrylamide  
375mM Tris-HCl, pH=8,8 
0,1% (w/v) SDS 
0,1% (w/v) APS 
0,1% (v/v) TEMED 
 
3.2.8. Immunoblotting 
Immunoblotting was performed to visualize proteins separated according to its 
size during SDS acrylamide gel electrophoresis. 
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3.2.9. Protein blotting 
Separeted on SDS acrylamide gel proteins were transferred into the nitrocellulose 
blotting membrane (0,45µM pores) using wet transfer technique. Transfer was performed 
in transfer buffer for 1h at 100V. 
 
Transfer buffer 
25mM Tris 
192mM Glycine 
20% (v/v)Methanol  
 
3.2.10. Protein detection 
Membranes with transferred proteins were blocked in 5% milk for 1h at room 
temperature. After blocking, membranes were incubated with appropriate primary 
antibody diluted in 5% milk overnight at 4˚C*. The next day, membrane were washed 3x 
for 10min with TBST and incubated for 1h with HRP-conjugated secondary antibody 
diluted in 5% milk* and washed 3x for 10min with TBST. Proteins on the membrane 
were detected using ECL Western Blotting Reagent (Amersham Bioscencies). In order to 
re-probe membranes with another antibody, membranes were stripped for 30min in 60˚C 
and used again for protein detection. 
 
*Primary and secondary antibody are listed in Appendix in Table 4. and Table 5.. 
 
20x TBS 
25mM Tris 
0,15M NaCl 
 
1xTBST 
1xTBS 
0,1% (v/v) Tween 20 
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Blocking milk solution 
5% non-fat dry milk 
1xTBST 
 
Stripping buffer 
62,5 mM Tris-HCl, pH=6,8 
2% (w/v) SDS 
100mM β-mercaptoethanol 
 
3.2.11. Densitometry 
cDNA and protein densitometry were performed using Biometra Illuminator and 
BioDoc software. cDNA and protein expression were normalized to GAPDH. 
 
3.2.12. PDE activity assay 
PDE assays were done by a modification of the two-step method by Thompson 
and Appleman.  Harvested cells were lysed in RIPA buffer (Santa Cruz) containing 
DMSO, protease inhibitor and PMSF. Lysates were incubated on ice for 30min and then 
subjected to a low-speed centrifugation (13000xg for 30 min) and aliquots of the resulting 
supernatant were used. 30µg of proteins were mixed with reaction buffer, appriopriate 
inhibitor and spiked with [3H]cAMP (Amersham Bioscencies), as a substrate. Assays 
were carried out at 37°C for 15min and then terminated by boiling for 3min in 100˚C. 
Samples were cooled down on ice and Crotalus Atrox venom at the final concentration of 
80µg/ml was added to prevent resynthesis of cAMP. Next, products of cAMP were 
separated from unhydrolysed substrate on chromatography columns filled with Sephadex-
Q25 beads. Scintillation liquid was added to each probe and radioactivity was measured 
using X software. 
Total PDE activity in cell lysates was determined and expressed as pmol of cAMP or 
cGMP hydrolysed per minute per mg of lysate protein. PDE activities were determined 
using specific inhibitors diluted in DMSO: IBMX as a non-specific PDE inhibitor, 
rolipram for PDE4, motapizone for PDE3, calcium/calmodulin as a stimulator of PDE1. 
 
Materials and methods 
________________________________________________________________________ 
 29 
Reaction buffer was as follows: 
Reagent Volume Final concentration 
1% BSA 10µl 0,01% 
40mM MgCl2 12,5µl 0,4mM 
1M HEPES, pH=7,6 10µl 0,2mM 
100µM cAMP 0,5µl 1µM 
Distilled H2O 22,5µl - 
 
Inhibitors used: 
Inhibitor Volume Final concentration 
4mM IBMX 5µl 40µM 
0,4mM Rolipram 2,5µl 1µM 
0,25 mM Motapizone 2µl 5µM 
10µM Cilomilast 6µl/ml 60 nM 
 
 
3.2.13. Immunocytochemistry 
Immunocytochemistry was performed for protein localization in the cells. Cells 
were seeded in 8-well chamber slides. After stimulation, cells were washed with 1xPBS. 
Cells were fixed in 1:1 methanol:acetone for 5min in room temperature. After washing 3x 
for 10min with PBS, cells were blocked in 5% PBS for 1h at room temperature and then 
incubated with appriopriate primary antibody* overnight at 4˚C. After washing 3x for 
10min with PBS and 1h incubation with FITC-conjugated secondary antibody*, cells 
were incubated with DAPI  for 5min at room temperature and covered with mounting 
medium. Visualization of protein localization was performed using fluorescent 
microscopy and Leica software. 
 
*Primary and secondary antibody are listed in Appendix in Table 4. and Table 5.. 
 
Blocking solution 
5% BSA 
1x PBS 
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3.2.14. Reactive oxygen species measurements 
Superoxide release from A549 was measured using the superoxide sensitive dye 
DHE. The cells were grown on chamber slides and cultured in medium alone, medium of 
0.1% FCS supplemented with TGF-β1 alone (2 ng/ml), TGF-β1 (2 ng/ml) and rolipram 
(1µM), TGF-β1 (2 ng/ml) and NAC (5mM), or H2O2 alone (1mM,or 10mM) for 24h. 
H2O2 treatment served as the positive control, whereas NAC treatment served as the 
negative control. Subsequently the cells were incubated with of DHE (5 µM) for 30min. 
The cells were washed with PBS, fixed in 1:1 methanol:acetone for 10min and stained 
with the nuclear stain DAPI. Cells were visualized under fluorescent microscopy 
(excitation: 514 nm; emission: 560 nm). A total of 10 images were captured from each 
group and in each image the total fluorescence-integrated density was analysed from all 
groups, respectively, in a blinded fashion using Image J software. 
 
3.2.15. Statistical analysis 
Data are expressed as the mean ± SEM. Statistical comparisons between two 
populations were performed using paired and unpaired Student t-tests where appropriate 
or by one-way ANOVA in combination with a Student-Newman-Keuls post-hoc test, 
which was used to compare differences between multiple groups, with a probability value 
of P<0.05 considered to be significant. 
 
3.2.16. Cell culture condition 
The A549 cell line was obtained from ATCC, Manassas, USA.  
A549 cells were grown on 10cm2 dishes in DMEM-F12 supplemented with 10% 
FCS, 5% streptomycin/penicillin, 5% vitamins, and 5% non-essentials amino acids, at 
37˚C, 5% CO2 and 95-100% humidity. After achieving 80-90% of confluence cells were 
passaged as follows: first cells were washed 1x with PBS and then incubated with 3ml 
Trypsin/EDTA for 2-3min to detach the cells. Next, 10% FCS culture medium was added 
to neutralize effect of Trypsin, the cells were counted and cell suspension was seeded on 
new plate culture dishes. 
Cells were cultured from the time of plating in medium alone, and medium 0.1% FCS 
supplemented with TGF-β1 (2ng/ml) for 24h. For experiments with rolipram, cells were 
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pretreated with different concentrations of Rolipram (100nM or 1µM) for 12h followed 
by TGF-β1 (TGF-β1) stimulation. For experiments with Y27632, cells were pretreated 
with Y27632 (10µM) for 12h followed by TGF- β1 (2ng/ml) stimulation. 
 
10% FCS cell culture medium 
F-12 DMEM Medium 
1% vitamins 
1% non-essentials amino acids 
1% Penicillin/Streptamycin 
1% Glutamine 
10% FCS 
 
0,1% FCS cell culture medium 
F-12 DMEM Medium 
1% vitamins 
1% non-essentials amino acids 
1% Penicillin/Streptomycin 
1% Glutamine 
10% FCS 
 
1x Trypsin/EDTA  
0,025% Trypsin/EDTA 
1xPBS 
 
Cells stimulation/treatment was as follows: 
Reagent Volume 
(per 1ml of medium) 
Final concentration 
2ng/µl TGF-β1 1µl 2ng/ml 
1mM Rolipram 1µl 1µM 
2mM NAC 5µl 10mM 
1µM Y27632 10µl 10µM 
30 % H2O2 1:1000000 10µM 
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4. Results 
4.1. Cell morphology and phenotype during EMT in A549 
cells 
4.1.1. Morphological changes 
To investigate potential changes in cell morphology, A549 cells were stimulated 
with TGF-β1 (2ng/ml) for 24 h. Cell morphology was examined using phase contrast 
microscopy. A549 cells in the absence of TGF-β1 exhibited a cubic, epithelioid shape 
and cluster formation, the typical features of epithelial cells (Figure 4.1.). Upon TGF-β1 
stimulation for 24 h, phase contrast microscopy revealed that cells underwent a 
morphological change, from cobblestone-like cell morphology to an elongated and 
spindle-like morphology, and reduced their cell-cell contact. 
 
Figure 4.1. Effects of TGF-β1 on cell morphology. 
A549 cells were stimulated with TGF- β1 (2ng/ml) for 24 h. Cell morphology was examined using phase 
contrast microscopy. 
 
 
4.1.2. Expression analysis of epithelial markers 
To further investigate changes caused by TGF-β1, mRNA and protein expression 
was analyzed. Both mRNA and proteins were isolated from control A549 cells and cells 
stimulated with TGF-β1 (1ng/ml and 2ng/ml) for 24 h. 
The analysis of expression on the mRNA level was performed by means of semi-
quantitative RT-PCR. The mRNA expression of epithelial phenotype markers, E-cadherin 
(E-Cad), cytokeratin-18 (Cyt 18), and zona occludins-1 (ZO-1) were significantly altered 
in TGF-β1 stimulated cells compared to control cells. TGF-β1 stimulation significantly 
Control TGF-β1 [2ng/ml] 
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decreased E-cadherin expression in a concentration-dependent manner. Concentrations as 
low as 1 ng/ml of TGF-β1 induced at least a 2 fold downregulation of E-Cad, Cyt-18 and 
ZO-1 expression (Figure 4.2. A, B).  
Similarly, immunoblotting confirmed decreased protein expression of both E-cadherin 
and cytokeratin-18 in TGF-β1 stimulated cells (Figure 4.2. C, D).  
 
 
 
 
Figure 4.2.  Effect of TGF-β1 stimulation on epithelial phenotype marker expression.  
Expression levels of mRNA from control and TGF-β1 (1ng/ml and 2ng/ml) treated A549 cells for 24h 
assessed by semi-quantitative PCR. GAPDH served as a control gene. A. mRNA expression of epithelial 
markers, B. Densitometric analysis of mRNA expression of epithelial markers, C. Protein expression of 
epithelial markers, D. Densitometric analysis of protein expression of epithelial markers.  
All values are given as the mean ± SEM (n=4) and are normalized to GAPDH. * p<0.05; ** p<0.01; *** 
p<0.001 versus control. 
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4.1.3. Expression analysis of mesenchymal markers 
In order to further study changes caused by TGF-β1, mesenchymal markers 
expression was analyzed on mRNA and protein level. Both mRNA and proteins were 
isolated from control A549 cells and cells stimulated with TGF-β1 (1ng/ml and 2ng/ml) 
for 24 h. 
RT-PCR was performed to examine the mRNA levels of mesenchymal markers as shown 
on Figure 4.3. A and B. We observed that TGF-β1 significantly increased mRNA 
expression of the mesenchymal markers collagen I (Coll I), fibronectin-EDA (Fn-EDA) 
and α-smooth muscle actin (α-SMA) in a concentration-dependent manner. However, the 
extent of α SMA expression at low concentrations of TGF-β1 was not as profound as Fn-
EDA and Coll I.  
In line with the mRNA expression, protein levels of those markers revealed increase after 
TGF-β1 treatment compared to control cells (Figure 4.3. C, D). 
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Figure 4.3. Effect of TGF-β1 stimulation on mesenchymal phenotype marker expression. 
Expression levels of mRNA from control and TGF-β1 (1ng/ml and 2ng/ml) treated A549 cells for 24h 
assessed by semi-quantitative PCR. GAPDH served as a control gene. A. mRNA expression of 
mesenchymal markers, B. Densitometric analysis of mRNA expression of mesenchymal markers, C. 
Protein expression of mesenchymal markers, D. Densitometric analysis of protein expression of 
mesenchymal markers  
All values are given as the mean ± SEM (n=4) and are normalized to GAPDH. * p<0.05; ** p<0.01; *** 
p<0.001 versus control.  
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4.2. PDE expression during TGF-β1 induced EMT  
To investigate potential influence of TGF-β1 treatment on PDE isoforms, mRNA 
expression of all 11 PDE families was analyzed. The mRNA was isolated from control 
A549 cells and cells stimulated with TGF-β1 (1ng/ml and 2ng/ml) for 24 h.  
Semi-quantitative PCR demonstrated an increase in mRNA expression of four 
PDE isoforms in TGF-β1 stimulated cells compared with control: PDE4A, PDE4D, 
PDE7A, and PDE10A, with PDE4D showing the most prominent increase in mRNA. In 
contrast, PDE1A and PDE3A expressions were decreased by TGF-β1 stimulation (Figure 
4.4 A, B). 
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Figure 4.4. mRNA expression of multiple phosphodiesterase (PDE) isoforms during TGF-β1 
induced epithelial mesenchymal transition (EMT). 
Expression levels of mRNA from control and TGF-β1 (1ng/ml and 2ng/ml) treated A549 cells for 24h 
assessed by semi-quantitative PCR. GAPDH served as a control gene. A. mRNA expression of PDE 
isoforms, B. Densitometric analysis of mRNA expression of PDE isoforms. All values are given as the 
mean ± SEM (n=4) and are normalized to GAPDH. * p<0.05; ** p<0.01; *** p<0.001 versus control. 
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4.3. PDE activity during TGF-β1 induced EMT  
In order to investigate whether the dramatic changes in mRNA expression of 
PDE1, PDE3, PDE4, PDE7 and PDE10 resulted in changes in activity of this enzymes, 
PDE activity assay was performed (Figure 4.5). 
A549 cells were treated with TGF-β1 (2ng/ml) for 24 h. Using cAMP-PDE inhibitors 
[non-specific PDE inhibitor, 30 µM IBMX; PDE1, calmodulin in addition of excess 
calcium in the presence of EGTA; PDE3, 10 µM motapizone; PDE4, 10 µM rolipram], 
we calculated the relative contribution of each isoform to the total cAMP-PDE activity. 
Total PDE activity in cell lysates was determined and is expressed as pmol cAMP 
hydrolysed per minute per mg of lysate protein. 
Interestingly, total cAMP-PDE activity was increased 2 fold in TGF-β1 stimulated cells 
compared with control (Figure 4.5). We calculated the relative contribution of each 
isoform to the total  activity and we found PDE4 to be the major contributor to cAMP-
PDE activity. In addition, PDE3 and PDE4 activities were also increased in TGF-β1 
stimulated cells compared with control and other cAMP-PDE isoforms. 
 
Figure 4.5. cAMP-PDE activities during TGF-β1 induced EMT. 
A549 cells were treated with TGF-β1 (2ng/ml) for 24 h. Using cAMP-PDE inhibitors [PDE1, addition of 
excess calcium in the presence of EGTA and 30 µM 8-MM-IBMX; PDE2, 10 µM EHNA in the presence of 
excess cGMP; PDE3, 10 µM milrinone; and PDE4, 10 µM rolipram]. Total PDE activity and is expressed 
as pmol cAMP hydrolysed per minute per mg of lysate protein. All values are given as the mean ± SEM 
(n=4) and are normalized to GAPDH. * p<0.05; ** p<0.01; *** p<0.001 versus control 
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ERK and PKA are known for activation PDE4 family by phosphorylation25,29,32. 
In order to check possible regulation of ERK and PKA by TGF-β1, immunoblotting 
analysis was performed (Figure 4.6). We couldn’t detect either PKA nor P-PKA in 
control A549 cells, as well as in TGF-β1 treated cells. Results obtained from ERK 
immunoblotting demonstrated that after TGF-β1 stimulation ERK is strongly 
phosphorylated as compared to control, wheras no changes were observed in total ERK 
level (Figure 4.6.).  
 
 
 
 
 
 
 
Figure 4.6. Protein expression of ERK and P-ERK during TGF-β1 induced EMT. 
Protein expression levels of total ERK and P-ERK from control and TGF-β1 (2ng/ml) treated A549 cells 
for 24h assessed by IB. Total ERK served as a protein loading control. A. Protein expression of ERK and 
P-ERK, B. Densitometric analysis of protein expression of P-ERK. 
All values are given as the mean ± SEM (n=4) and are normalized to total ERK. * p<0.05; ** p<0.01; *** 
p<0.001 versus control. 
 
 
 
4.4. Expression of PDE4 isoforms in TGF-β1 induced EMT 
To support our previous observations, protein expression and cell localization of 
PDE4 isoforms was analyzed. 
Protein expression was detected by immunoblotting and subsequent densitometric 
quantification of PDE4 isoforms (PDE4A and PDE4D) in TGF-β1 (1ng/ml and 2ng/ml) 
stimulated and control cells for 24 h (Figure 4.7). Imunoblotting demonstrated 
upregulation of both PDE4Ax isoform and PDE4D isoforms compared to control.  
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Figure 4.7. Protein expression of PDE4 isoforms during TGF-β1 induced EMT. 
Protein expression levels of control and TGF-β1 (1ng/ml and 2ng/ml) treated A549 cells for 24h assessed 
by IB. GAPDH served as a protein loading control. Gels are representative for three independent 
experiments. A. Protein expression of PDE4 isoforms, B. Densitometric analysis of protein expression of 
PDE4 isoforms.All values are given as the mean ± SEM (n=4) and are normalized to GAPDH. * p<0.05; ** 
p<0.01; *** p<0.001 versus control. 
 
4.5. Localization of PDE4 isoforms in TGF-β1 induced EMT 
Additionaly, localization of PDE4 isoforms (PDE4A and PDE4D) in TGF-β1 
(1ng/ml and 2ng/ml) stimulated and control cells for 24 h, was analyzed by 
immunocytochemistry (Figure 4.8). Results displayed PDE4A and PDE4D-like 
immunoreactivity in the cytoplasm. PDE4A was sometimes found to be diffusely present 
in the membrane of the A549 cells. 
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Figure 4.8. Localization of PDE4A and PDE4D isoforms in TGF-β1 induced EMT  
PDE4A and PDE4D localization visualized with secondary FITC-labelled antibody (green). Cell nuclei 
were visualized with DAPI (blue). A549 cells were grown in serum-free medium or stimulated with TGF- 
β1 (2ng/ml) for 24 h.  
 
 
 
4.6. Effect of PDE4 inhibition on TGF-β1 induced EMT 
On the basis of the prominent increase in the mRNA and protein expression of 
PDE4A and PDE4D as well as PDE4 activity, during TGF-β1 induced EMT, we assessed 
the role of the PDE4 family by using the specific pharmacological inhibitor, Rolipram.  
A549 cells were pre-treated with the PDE4 inhibitor, Rolipram (100nM or 1µM) for 12 h 
followed by TGF-β1 (2ng/ml) stimulation for 24h or stimulated with TGF-β1 (2ng/ml) 
alone.  
mRNA expression was analyzed by semi-quantitative PCR and subsequent densitometric 
quantification of epithelial and mesenchymal phenotype markers, (E-Cad, Cyt 18, α-
SMA, Coll I and Fn-EDA) in the above treated cells. 
Figure 4.9 shows changes in both epithelial and mesenchymal phenotype markers in 
TGF-β1 stimulated A549 cells after treatment with Rolipram. Rolipram (100nM and 
1µM) significantly decreased the mRNA expression of mesenchymal markers Coll I and 
Fn-EDA in a concentration dependent manner (Figure 4.9 A, C). Incubation of cells with 
Rolipram (1µM) also helped to restore mRNA expression of the epithelial marker E-Cad, 
but not Cyt-18 (Figure 4.9. A, B). 
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Figure 4.9. Analysis of mRNA expression of epithelial and mesenchymal markers in PDE4 
inhibited TGF-β1 induced EMT. 
Expression levels of mRNA from control, A549 cells pre-treated with Rolipram (1µM) for 12 h followed 
by TGF-β1 (2ng/ml) stimulation for 24h or A549 cells stimulated with TGF-β1 (2ng/ml) alone, were 
assessed by semi-quantitative PCR. GAPDH served as a control gene. A. mRNA expression of epithelial 
and mesenchymal markers, B. Densitometric analysis of mRNA expression of epithelial markers, C. 
Densitometric analysis of mRNA expression of mesenchymal markers. 
All values are given as the mean ± SEM (n=4) and are normalized to GAPDH. * p<0.05; ** p<0.01; *** 
p<0.001 versus control; † p<0.05; †† p<0.01; ††† p<0.001 versus TGF-β1 stimulated cells 
 
 
 
Similarly, immunoblotting suggested downregulation of E-Cad (1.5 fold) and 
upregulation of Fn-EDA (1.7 fold) with TGF-β1 stimulation. Treatment with Rolipram 
restored both E-Cad and Fn-EDA expression to nearly a normal level compared with 
TGF-β1 stimulated cells (Figure 4.10 A, B), thus demonstrating that PDE4 inhibition 
potentially abrogates TGF-β1 induced EMT. 
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Figure 4.10. Analysis of protein expression of epithelial and mesenchymal markers in PDE4 
inhibited TGF-β1 induced EMT.  
Protein expression levels of mesenchymal markers from control, A549 cells pre-treated with Rolipram 
(1µM) for 12 h followed by TGF-β1 (2ng/ml) stimulation for 24h or A549 cells stimulated with TGF-β1 
(2ng/ml) alone, were assessed IB. GAPDH served as a protein loading control. A. Protein expression of 
epithelial and mesenchymal markers, B. Densitometric analysis of mRNA expression of epithelial and 
mesenchymal markers. 
All values are given as the mean ± SEM (n=4) and are normalized to GAPDH. * p<0.05; ** p<0.01; *** 
p<0.001 versus control; † p<0.05; †† p<0.01; ††† p<0.001 versus TGF-β1 stimulated cells 
 
 
 
In order to localize E-Cad, cytokeratin, α-SMA and fibronectin in the cells, we 
performed immunocytochemistry analysis (Figure 4.11). Cells were treated as above. 
Results revealed that membrane localized E-Cad, completely disappeared after TGF- β1 
stimulation, wheras pre-treatment with Rolipram partly restored its expression. Level of 
cytosolic fibronectin was strongly increased after TGF- β1 stimulation, whereas pre-
treatment with Rolipram abolished its expression. Rolipram pre-treatment had no 
significant effect on cytokeratin and α-SMA expression and localization. 
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Figure 4.11. Localization of epithelial and mesenchymal markers in PDE4 inhibited TGF-β1 
induced EMT. 
E-Cad, Cytokeratin, Fibronectin and α-SMA localization visualized with secondary FITC-labelled antibody 
(green). Cell nuclei were visualized with DAPI (blue). A549 cells were grown in serum-free medium alone, 
or pre-treated with Rolipram (1µM) for 12 h followed by TGF-β1 (2ng/ml) stimulation for 24h or 
stimulated with TGF-β1 (2ng/ml) alone. 
 
 
4.7. Effect of PDE4 inhibition on Smad signaling 
TGF-β1 can regulate its target genes via Smad-dependent pathways that include 
recruitment TGF-β1 receptors and phosphorylation of Smad 2 and Smad 3.   
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To investigate whether Rolipram is influencing Smad signaling pathway, A549 
cells were pre-treated with the PDE4 inhibitor, Rolipram (100nM or 1µM) for 12 h 
followed by TGF-β1 (2ng/ml) stimulation for 24h or stimulated with TGF-β1 (2ng/ml) 
alone.  
The effects of Rolipram on the activation of the Smad signaling pathway in A549 cells by 
TGF-β1 were studied by immunoblotting with Smad 4, phospho-Smad 2, phospho-Smad 
3, and TGF-β1 type II receptor (TGF-β1 RII) antibodies. Phosphorylation of Smad 2 and 
Smad 3 protein increased in A549 cells upon TGF-β1 stimulation for 24 h; however, 
these increase was not blocked by treatment with Rolipram (Figure 4.12 A, B). Likewise, 
Smad 4 and TGF-β1 RII protein levels increased after TGF-β1 stimulation, and this 
increase was not blocked by Rolipram, indicating that PDE4 inhibitor did not inhibit 
TGF-β1 induced EMT through Smad-dependent pathway..  
 
 
 
Figure 4.12. Effect of PDE4 inhibition on TGF-β1 induced Smad signaling. 
Protein expression levels of P-Smad 2, P-Smad 3, Smad 4 and TRβ II, from control, A549 cells pre-treated 
with Rolipram (1µM) for 12 h followed by TGF-β1 (2ng/ml) stimulation for 24h or A549 cells stimulated 
with TGF-β1 (2ng/ml) alone, were assessed by IB. GAPDH served as a protein loading control. A. Protein 
expression of Smad proteins and TRII, B. Densitometric analysis of protein expression of Smad proteins 
and TRII  
All values are given as the mean ± SEM (n=4) and are normalized to GAPDH. * p<0.05; ** p<0.01; *** 
p<0.001 versus control. 
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4.8. Effect of PDE4 inhibition on TGF-β1 induced ROS 
production 
Since TGF-β1 was already shown to be able to induce ROS generation54 and 
PDE4 involvement in this process was also suggested55, we analyzed the effect of 
Rolipram in TGF-β1 induced EMT on ROS production. 
To assess the role of ROS, DHE immunofluorescence was performed on cells 
treated with H2O2 (1mM and 10mM), TGF-β1 and/or Rolipram for 24 h. As shown in 
Figure 4.13, H2O2 used as a positive control increased ROS production in a 
concentration-dependent manner compared to control. Interestingly, TGF-β1 treatment 
induced ROS production, whereas co-treatment with Rolipram blocked the TGF-β1 
mediated increase in ROS production. 
 
Figure 4.13. Effect of PDE4 inhibition on ROS production. 
Reactive oxygen species (ROS) production was measured by dihydroethidium (DHE) fluorescence in 10 
randomly selected images from each group. A549 cells were treated with TGF-β1 (2ng/ml) for 24h, 
Rolipram (100nM and 1µM) pre-treatment for 12h and then TGF-β1 (2ng/ml) for 24h or H2O2 (1mM or 
10mM) for 12 h as a positive control. 
All values are given as the mean ± SEM (n=4) and are normalized to GAPDH. * p<0.05; ** p<0.01; *** 
p<0.001 versus control, † p<0.05; †† p<0.01; ††† p<0.001 versus TGF-β1 stimulated cells. 
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4.9. Effect of ROCK inhibition 
Since TGF-β1 stimulation increased the expression of ROCK1 in A549 cells, we 
assessed the involvement of Rho/ROCK signaling by using a specific pharmacological 
inhibitor of ROCK, Y27632. A549 cells were pre-treated with the Y27632 (100nM) for 
12 h followed by TGF-β1 (2ng/ml) stimulation for 24h or stimulated with TGF-β1 
(2ng/ml) alone.  
Treatment with Y27632 partially abrogated TGF-β1 induced EMT and restored the 
expression of E-Cad. Most importantly, PDE4D protein level increased after TGF-β1 
stimulation was decreased by Y27632 treatment (10µM) (Figure 4.14).  
 
 
 
Figure 4.14. Effect of ROCK inhibition on TGF-β1 induced EMT. 
Protein expression levels of E-Cad and PDE4D from control, A549 cells pre-treated with Rolipram (1µM) 
for 12 h followed by TGF-β1 (2ng/ml) stimulation for 24h or A549 cells stimulated with TGF-β1 (2ng/ml) 
alone, were assessed by IB. GAPDH served as a protein loading control. A. Protein expression of E-Cad 
and PDE4D, B. Densitometric analysis of E-Cad and PDE4D.  
All values are given as the mean ± SEM (n=4) and are normalized to GAPDH. * p<0.05; ** p<0.01; *** 
p<0.001 versus control; † p<0.05; †† p<0.01; ††† p<0.001 versus TGF-β1 stimulated cells. 
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5. Discussion 
5.1. TGF-β1 induced EMT in A549 cells 
The epithelial mesenchymal transition has emerged as a critical event not only in 
development, but also in wound healing, fibrosis, and the invasion and metastasis of 
tumor cells2,5,56. Moreover, it has been recently established that EMT is critically 
involved in organ fibrosis, including the lung. It is increasingly being recognized that, 
following epithelial injury, epithelial cells can give rise to fibroblasts and thereby 
contribute to the pathogenesis of pulmonary fibrosis by undergoing EMT57,58. Similarly, 
EMT involvement in lung cancer has been recently reported to promote the migratory and 
invasive abilities of lung cancer cells, attributes essential for tumor metastasis59. 
Although a growing number of studies have shown the occurrence of EMT in vivo and in 
vitro, very little is known about mediators and molecular mechanisms involved in EMT. 
Better understanding and explanation of underlying mechanism and regulation of this 
process is being currently growing area of study. 
TGF-β is considered as an important regulator of cell proliferation, differentiation, 
apoptosis, immune response, and extracellular matrix remodeling, depending on 
physiological context. Moreover, TGF-β1 has been shown as a major inducer of EMT in 
many organs such as lung1,60-62, kidney63, skin64 and liver24. 
A549 cells retain important characteristics of alveolar type II epithelial cells and 
are among the best-characterized alveolar epithelial cells. They have been used in a 
number of studies to investigate promoter activity, apoptosis and alveolar epithelial cell 
DNA damage as well as various aspects of EMT8,65,66. The ability of TGF-β1 to promote 
EMT in A549 cells was reported in several studies8,67,68.  
In the present study we could observe that exposure of A549 cells to TGF-β1 for 
24 h induced a complete conversion of the epithelial cells to myofibroblasts, as evidenced 
by the acquisition of a spindle-like morphology and loosing typical epithelial morphology 
– layers formation, cell to cell contact and cuboic shape (Figure 4.1). This is in line with 
the observed elevated expression of mesenchymal marker genes (fibronectin, desmin and 
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α-smooth muscle actin) and at the same time loss of epithelial marker genes (E-cadherin, 
zona occludins-1, cytokeratin 18) (Figures 4.2 and 4.3).  
We investigated the effect of two different concentrations of TGF-β1 - 1ng/ml and 
2ng/ml, since previous studies show diversity in TGF-β1 concentrations used to induce 
EMT. We could observe that already as low concentration as 1ng/ml is sufficient to 
induce A549 to undergo EMT.  
The time frame required for this transition was 24 h. Changes in epithelial and 
mesenchymal phenotypic markers on mRNA level as well as on protein level, illustrated 
that 24 h is sufficient time for TGF-β1 to induce EMT in A549 cells and our results were 
similar to previous reports8.  
Data from current study indicates that A549 cells undergo EMT and that TGF-β1 is the 
inducer of this process. This findings are in line with numerous studies8,69,70. 
 
5.2. PDEs in TGF-β1 induced EMT in A549 cells 
Cyclic nucleotide phosphodiesterases through hydrolyzing cAMP and/or cGMP 
propagate many signaling pathways, including proliferation, migration, and 
differentiation27,37,71,72. 
Furthermore, epithelial and mesenchymal phenotype marker genes that are altered 
during EMT by TGF- β1 can be influenced by increased cAMP or cGMP levels. cAMP 
acts directly via reducing activation of collagen gene transcription, but also the 
expression of α-smooth muscle actin73. It was also demonstrated that cAMP is able to 
abolish the TGF-β1-induced reorganization of the actin cytoskeleton and inhibits the 
disruption of the E-Cadherin cell to cell interactions74. Stimulator of cGMP synthesis, 
nitric oxygen (NO), is able to conserve epithelial morphology, decrease collagen I 
expression, and keep the epithelial markers E-Cadherin and pro SP-B in the face of TGF- 
β1 exposure75.  
Concerning all of this reports, investigations of possible role of PDEs in EMT seems very 
promising.  
Additionaly, PDEs have been already shown to be involved in several diseases, 
including lung.  
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In lung cancer PDEs have been shown to be involved in apoptosis. PDE1 and PDE5 
isoforms were found to be highly expressed in orthotopic tumors and their inhibition 
resulted in decreased proliferation and increased apoptosis within the tumor76.  
Concerning pulmonary fibrosis, it has been demonstrated that PDE5 is highly upregulated 
in transition of fibroblast to myofibroblast and that PDE4 inhibition can block the process 
of differentiation77. In cystic fibrosis, PDE4 is involved in signaling in apical membrane 
patches during cell-attached recordings in airway epithelium78. 
Also current findings in pulmonary arterial hypertension (PAH) demonstrate that PDEs 
play an important role in smooth muscle contraction and relaxation. PDE3 was shown to 
influence pulmonary vasodilatation in intact rabbits with elevated pulmonary artery 
pressure, PDE1 and PDE5 are strongly upregulated in the pulmonary artery media of 
human lungs with severe pulmonary hypertension, and PDE4 inhibition reversed 
pulmonary hypertension and right heart hypertrophy in rats 79-82.  
 
5.2.1.PDE expression in TGF-β1 induced EMT 
As PDEs proofed to be an important target on the single cell level as well as in 
several lung diseases, we found interesting to examine expression profile of those 
enzymes during TGF-β1 induced EMT in A549 cells. 
To date, present study is the first one investigating the involvement of PDEs in 
TGF-β1 induced EMT process.  
We investigated an effect of two concentrations of TGF-β1 on A549 cells. Our 
results indicated that TGF-β1 brought changes in PDE expression. Among 11 PDE 
families, TGF-β1 effects mostly PDE1A, PDE3A, PDE4A, PDE4D, PDE7A and 
PDE10A family, causing increased expression on mRNA level of PDE4A, PDE4D, 
PDE7A and PDE10A isoforms, wheras decreased expression of PDE1A and PDE3A 
isoforms. To our observations, PDE4D show the most prominent increase in mRNA 
(Figure 4.3).  
There are no reports describing any correlation between PDE4 and EMT, but it was 
demonstrated that elevated levels of cAMP had influence on EMT83,84. Since PDE4 is 
cAMP specific it suggests that cAMP-PDEs may be involve in this process as well.  
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5.2.2.PDE activation in TGF-β1 induced EMT 
Above findings suggested that TGF-β1 is able to regulate PDEs expression. To 
further investigate the influence of TGF-β1 treatment on PDEs and in particular on their 
functional properties , activity of those enzymes was examined. 
We found the most striking 2 fold increase in total cAMP-PDE activity after TGF-β1 
stimulation. We observed that PDE4 family contributed the most to the total activity. 
Additionaly, PDE4 activity increased more then 2 fold (Fig. 4.5). These results were in 
line with mRNA expression, where we could observe the strongest increase in PDE4 
family (PDE4A and PDE4D) and PDE3 family (PDE3A). Both of them are cAMP 
specific.  
There are no reports so far exploring direct effect of TGF-β1 on PDE4 activity, 
but previous studies demonstrated that PDE4 activation and induction, occurs as an effect 
of regulation of phosphorylation/dephosphorylation of PKA and/or ERK. What is also 
interesting, there are reports showing that TGF-β1 can regulate ERK and PKA activation. 
PKA phosphorylates serine residue in UCR1 at the N-terminal end of PDE4, and 
though activates long PDE4 isoforms45,46. It is believed that PKA phosphorylation in 
UCR1 causes disruption of interaction between UCR1 and UCR2 through conformational 
changes47. 
On the other hand, ERK regulates PDE4 activity via phosphorylation, causing inhibition 
as well as activation of PDE4. All PDE4 subfamilies, except PDE4A, contain in a 
catalytic domain a single ERK consensus motif (Pro-Xaa-Ser-Pro). It is already known in 
vitro and in vivo that serine from this motif can be phosphorylated by ERK49,50. 
Moreover, recent studies indicated that TGF-β1 can regulate ERK and PKA 
activation. It was demonstrated that in fetal lung fibroblasts, TGF-β is able to activate 
PKA. Moreover, TGF-β1 stimulates cell proliferation by activating the MEK-ERK 
pathway85. Elevated ERK activity can enhance Smad activity, and ERK inhibition 
reduces TGF-β1 stimulated Smad phosphorylation as well as collagen production and 
promoter activities. Additionally, cells of mesenchymal origin appear to show synergy in 
ERK-Smad interaction whereas epithelial cells generally appear to show inhibition86. But 
experiments on T-cells revealed that TGF-β1 can also decrease phosphorylation of ERK 
and thereby its activation87.  
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We investigated expression level of total PKA and its phosphorylated status in 
A549 cells after TGF-β1 treatment. Unfortunately, we were not able to detect either PKA 
nor phosphorylated form of PKA. 
We also investigated total ERK and its phosphorylated status in A549 cells after TGF-β1 
treatment. Our results indicated that upon TGF-β1 stimulation ERK is phosphorylated 
and though probably activated (Fig. 4.6). Thus, our observation that TGF-β1 treatment 
caused double increase in PDE activity, with the main contribution of PDE4, may be 
explained that TGF-β1 is able to regulate activation of PDE, and in particular PDE4, 
during EMT through ERK signaling pathway.  
 
5.2.3.PDE4 family in TGF-β1 induced EMT in A549 cells 
5.2.3.1. PDE4 expression 
As observed above, after TGF-β1 treatment PDE4 family is the one with the most 
prominent changes concerning expression on mRNA level as well as activation. Since 
PDE activity assay is unable to distinguish which PDE4 isoforms are the main 
contributors to total PDE4 activity, we checked the protein expression of PDE4 family. 
Our results were in line with mRNA expression, and we observed increase in expression 
of PDE4A and PDE4D isoforms - PDE4A expression was slightly increased, wheras 
PDE4D expression level was more then 2 fold increased (Fig. 4.7).  
 
5.2.3.2. PDE4 localization 
PDE4 is specific for cAMP and it has been reported that cAMP is 
compartmentalized in the cell. cAMP is generated at the cytosol surface of the plasma 
membrane through the action of membrane bound adenylate cyclases. Increased levels of 
cAMP are translated into cellular response through the action of PKA44. cAMP forms a 
gradients in the cell and the basis of such gradients will depend upon the activity of both - 
AC and PDEs32,44. It is now well recognized that AC are not evenly distributed across the 
cellular membrane. Since PDE4 control and regulate cAMP, localization of those 
Discussion 
________________________________________________________________________ 
 53 
enzymes may differ according to the gradients of cAMP. PDE4 activity was found in 
cytosol, membrane, nucleus and cytoskeletal locations32,44,88. 
Moreover, distribution of PDE4 in the cell is changing according to targeting molecule 
PDE4 is reacting with. It has been shown that PDE4 form a complex with β-arrestins, 
thereby providing a means of delivering PDE4 to the active site of cAMP synthesis in the 
plasma membrane44. Findings in cardiac myocytes concerning PDE4 interactions with 
AKAP, indicate that hypertrophic conditions causes the dynamic redistribution of PDE4 
from the cytosol into perinuclear compartment44,71. Other study show that PDE4 can 
interact with protein-tyrosine kinases (such as Src, Lyn, Fyn) and role of this interaction 
is intracellular targeting. Thus membrane associated PDE4A5 is found at the cell 
periphery where it is localized to ruffles and at a discreete perinuclear localization. But 
when interaction with kinases can not take place, PDE4A5 is distributed uniformly 
through the cell margin44. 
Concerning all of this reports, we performed an experiment to localize PDE4A 
and PDE4D in the cell before and after TGF-β1 treatment. Results displayed that PDE4A 
and PDE4D immunoreactivity were concentrated in the cytoplasm. Additionally, PDE4A 
was sometimes found to be diffusely present in the membrane of the A549 cells (Fig. 
4.8). These results are in agreement with recently published data indicating that PDE4A 
isoform is mostly found on the cellular membrane, wheras PDE4D is found mostly in 
cytosol32,44,88.  
Cytosolic and membrane localization of PDE4A and PDE4D may suggest that TGF-β1 
can directly regulate these PDEs via TGF-β1 receptors which are membrane-bound. 
Other possible explanation is that PDE4 is regulated by TGF-β1 indirectly via TGF-β1 
signaling components such as Smad proteins which are localized in cytosol.  
 
5.2.4. PDE4 inhibition in TGF-β1 induced EMT 
Our findings indicated that mRNA, protein and activation level of PDE4 family is 
strongly elevated by TGF-β1. To asses a potential effect of PDE4 inhibition on TGF-β1 
induced EMT, we investigated treatment with PDE4 selective inhibitor Rolipram.  
Rolipram is a specific PDE4 inhibitor which proved to be significantly more 
potent in inhibiting PDE4D than the other subtypes, in particular PDE4C89. Rolipram was 
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first used in mice and rats, and results from this investigation indicated that Rolipram 
show antidepressant activity90,91. Rolipram was also proofed to have anti-inflammatory 
activity. It has been shown to be a potent inhibitor of leukotriene and PGE2 production92. 
Although so promising at the beginning, Rolipram demonstrated to have too many side 
effects in vivo and currently is being used in vitro mostly. 
PDE4 inhibitors are known for suppressive activity on various in vitro and in vivo 
responses. In vitro they suppress production of cytokines, cell proliferation and 
chemotaxis, release of inflammatory mediators and NADPH activity. In vivo, attenuation 
of PDE has been shown to influence pathological processes by means of specific 
inhibitors which have demonstrated pre-clinical and clinical efficacy in the treatment of 
different lung diseases. PDE4 inhibitors are currently being developed in COPD, 
inflammatory diseases such as asthma, lung cancer, fibrosis and PAH33,82,93,94. 
In COPD, arthritis and asthma PDE4 inhibitors suppress multiple neutrophil responses, 
such as production of IL-8, leukotriene, and superoxide anions, degranulation, 
chemotaxis and adhesion. PDE4 inhibition reduces the transcriptional activity of the 
predominant genes involved in mucin secretion during inflammation95.  
In mice experimental model of autoimmune diabetes, PDE4 inhibition reduced severity 
of insulitis and prevented diabetes96 
In allergic diseases PDE4 inhibitors suppress eosinophil activity such as superoxide 
production, adhesion and infiltration into airways. In addition T cell proliferation and 
production of TNF-α, IL-2, IL-5, IL-4  and PGE2 are supported by PDE4 inhibition 95. 
PDE4 and its inhibition also seems to play o role during cystic fibrosis. Two independent 
reports demonstrated that PDE4D is involved in controling the function of 
transmembrane conductance regulator in pulmonary epithelial cells95. 
PDE4 inhibition is also proposed to play a role in leukemias through its antitumor and 
anti-angiogenic effects. PDE4 inhibitors shown to have antiproliferative activity on T 
cells and B cells as well as on murine carcinoma cells95. 
Recently it was also shown that PDE3/4 inhibition can partially reverse MCT-induced 
PAH in rats93.  
Moreover, PDE4 knock-out experiments demonstrated that  PDE4D-/- mice 
exhibit impaired airway contraction induced by cholinergic stimulation and abolished 
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airway hyperreactivity what is caused by exposure to allergen. This indicates a role of 
PDE4D in cholinergic airway responsiveness and in development of hyperreactivity34 
Silent finding of this study was that PDE4 inhibitor Rolipram exhibited a 
remarkable inhibitory effect on TGF-β1 induced EMT. Interestingly, these effects were 
observed with a PDE4 inhibitor at very low concentrations (100 to 1000 nM). This 
inhibition was partial, as evidenced by a restoration of epithelial morphology and E-
cadherin expression and a complete abolishment of fibronectin stimulation (Fig. 4.9 and 
4.10).  
We observed that on mRNA as well as on protein level, E-Cad expression was restored 
like in the control cells. Additionally, we were able to localize E-Cad in control A549 
cells in cytosol but mostly in cell membrane. After TGF- β1 stimulation E-Cad 
disappeared from cell membrane and was very slightly localized only in cytoplasm, 
wheras when Rolipram pre-treated we could observe that E-Cad expression level in 
cytoplasm dramatically increased. We could not detect membrane localization of E-Cad 
with Rolipram pre-treatment but tendency of gathering the cells in cluster-like origins 
was observed. Cytokeratin mRNA level was only slightly influenced by Rolipram. 
Cytokeratin fibers were very clearly visible in control A549 cells, wheras its 
disappearance was noticed after TGF- β1 treatment. Rolipram pre-treatment had no effect 
on TGF- β1 caused changes (Fig. 11). Our data demonstrating that E-cadherin expression 
is preserved in TGF-β1-exposed A549 cells, may have important implications in the 
prevention of EMT. E-Cad restoration may have serious implication during EMT – cell to 
cell contact via tight junction may be restored as well. As a result, migratory properties 
may be abolished. Therefore, inhibition of the TGF- β 1 induced downregulation of E-
cadherin by Rolipram may be a critical first step in the prevention of EMT. 
Concerning mesenchymal markers we could observe that Rolipram pre-treatment 
abolished fibronectin increase caused by TGF-β1 on mRNA as well as on protein level. 
Moreover, we were able to localize fibronectin in cytosol after TGF-β1 treatment, wheras 
no expression was observed in control cells. In the cells pre-treated with Rolipram 
fibronectin expression in cytosol was also not detectable anymore. Rolipram had no 
effect on α-SMA on mRNA level. When we localize α-SMA in the cell, it was expressed 
in cytoplasm after TGF-β1 treatment. No changes compare to TGF-β1 stimulation were 
observed with Rolipram pre-treatment. Fibronectin abolishment by Rolipram may be 
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important for blocking EMT process since fibronectin plays crucial regulatory roles in 
migration and in interactions with extracellular matrix components (Fig. 4.11). 
This is the first study showing direct effect of PDE4 inhibition on EMT. However, in 
general agreement with this results, similar observation were demonstrated in kidney 
epithelial cells where cAMP elevating agents, 8-Br-cAMP and forskolin exhibit an 
inhibitory effect on EMT83. Also cAMP directly acts  reducing activation of collagen 
gene transcription, but also the expression of α-smooth muscle actin73. It was also 
demonstrated that cAMP is able to abolish the TGF- β1-induced reorganization of the 
actin cytoskeleton and also inhibits the disruption of the E-Cadherin cell to cell 
interactions74. 
 
5.2.5. PDE4 inhibition and Smad signaling 
TGF-β1 network involves receptor serine/threonine kinases at the cell surface and 
their substrates, the Smad proteins. Each ligand of the TGF-β family binds to specific 
pairs of receptor serine/threonine kinases, belonging to groups known as the type I and 
type II receptors, respectively. Most mammalian cells express different members of this 
receptor family, some of which may be shared by different TGF-β ligands.When the 
ligand binds, it acts as a dimeric assembly factor, bringing together two type I and two 
type II receptors. In this complex, receptor II exerts its only known function, which is to 
activate receptor I by phosphorylation. The type I receptor then phosphorylates Smad 
proteins that propagate the signal. Once phosphorylated  by the activated TGF-β1 
receptor, Smad2 and/or Smad3 complex with Smad4 and move into the nucleus, where 
they activate target gene transcription in association with DNA-binding partners. One 
mechanism for switching off the TGF-β signal involves Smad ubiquitylation in the 
nucleus, followed by proteasome-mediated degradation of the Smad protein. A separate 
ubiquitylation mechanism controls the basal level of Smad through the ubiquitin ligase 
Smad ubiquitylation regulatory factor (SMURF1). A more common mechanism for 
returning a phosphorylated mediator to its basal state, protein dephosphorylation, has not 
been described for the deactivation of Smads16,97.  
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As mentioned already above, it was shown that TGF-β1 can activate ERK via 
interaction of Smad pathway on ERK directly86. ERK phosphorylates and thus activates 
PDE4, but there are no reports demonstrating correlation between PDE4 and its 
inhibition, and Smad pathway.  
It was also reported that TGF-β1 induced fibroblast to myofibroblast differention was 
blocked by PGE2 in Smad independent manner. Stimulation with PGE2 limited collagen I 
and α-SMA expression, whereas had no effect on translocation of Smad 2/Smad 3 
complex to the nucleus. Therefore it suggest that cAMP plays a role in TGF-β1 non-
Smad signaling pathways. Moreover; PGE2  was reported to block any of the well known 
signal transduction events that occur as a result of TGF-β1 stimulation in fibroblasts98,99. 
What was also interesting, is the report that cells of mesenchymal origin appear to 
show synergy in ERK-Smad interaction whereas epithelial cells generally appear to show 
inhibition86. 
In our study we show that TGF-β1 caused increase in PDE4 expression and 
activity. Moreover, PDE4 inhibition during TGF-β1 induced EMT can partially reverse 
this process. But since direct correlation between PDE4 pathway and Smad signaling 
were not demonstrated so far, we investigated Smad expression during TGF-β1 induced 
EMT as well as during PDE4 inhibited TGF-β1 induced EMT. We found that TGF-β1 
induces Smad 2 and Smad 3 phosphorylation in A549 cells, as has been shown by several 
other groups16,17,85. Interestingly, these phosphorylation events are not altered by PDE4 
inhibition, suggesting that PDE4 inhibitors may use alternative Smad-independent 
pathways to regulate EMT marker genes (Fig. 4.12).  
These observation are in agreement with the data demonstrated that in fibroblasts cAMP 
elevation through PGE2 does not block translocation of Smad 2/Smad 3 complex to the 
nucleus. Moreover, elevation of cAMP levels by PGE2 was accompanied by changes in 
cell shape, cell adhesion to the matrix and cytoskeletal organization and it occur also in 
Smad independent way100-102. 
 
Discussion 
________________________________________________________________________ 
 58 
5.3. PDE4 family and ROS generation 
Reactive oxygen species (ROS) such as hydrogen peroxide (H2O2), superoxide 
anion, and hydroxyl radical are generated as byproducts of the metabolism of oxygen. 
There is a growing evidence that ROS play important roles as a second messenger in 
signal transduction in processes including wound repair, host defense, blood vessel 
relaxation, and neurotransmission103. 
Increased generation of ROS can occur when inflammatory cells such as neutrophils, 
eosinophils and macrophages are recruited to the alveolar spaces, either in response to 
toxins or antigens or as a consequence of infection. Data obtained from cell culture 
studies indicates that after exposure to prooxidants, lung epithelial and endothelial cells 
are able to generate ROS. Various experimental models strongly support the hypothesis 
that oxidative stress generated by these agents and inflammatory cells can lead to the 
development of many acute and chronic airway diseases, including fibrosis, asthma, 
emphysema, acute respiratory distress syndrome (ARDS), and bronchial 
carcinogenesis104. 
Considering the established role of both, PDE4 and TGF-β1, in ROS generation, 
we postulated ROS signaling to be a candidate mediator of the PDE4 inhibitory effects on 
EMT. 
PDE4 inhibition triggered a cAMP-independent inhibition of ROS55. It was also reported 
that elevation of cAMP produces the inhibition of different inflammatory processes, such 
as cellular trafficking, cytokine release or reactive oxygen species production105. What is 
also interesting, PDE4 inhibition has been linked already with inhibition of ROS 
generation. Data obtain from experiments performed in macrophages and A549 cells, 
suggest that ROS-mediated lung inflammation could be mediated at least in part by 
elevated PDE activity associated with decreased cAMP in those cells106.  
Also TGF-β1 influence on ROS production was already reported. ROS have been shown 
to mediate TGF-β1 induced cellular responses in various cells54,107-109. Moreover, it has 
been demonstrated that antioxidants effectively reversed TGF-β1 induced Smad 2 
phosphorylation as well as changes in E-Cad and α-SMA expression54.  
Consistent with our hypothesis, we found that TGF-β1 induced a threefold 
increase in DCF-sensitive cellular ROS, what confirmed previous reports. But to our 
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surprise, 1µM of PDE4 inhibitor Rolipram completely blocked TGF-β1 induced ROS 
production, thus establishing ROS as a target of PDE4 during EMT (Fig. 4.13). Our data 
strongly suggest that PDE4 inhibition has ability to reverse of EMT. Though PDE4 
inhibition was not directly correlated with TGF-β1 Smad dependent pathway, it seems 
that it is triggered via ROS.  
This results are similar to finding that inhibiting ROS production by antioxidants 
prevented changes in E-Cad and α-SMA54.  
 
5.4. PDE4 family and Rho kinases 
Members of the Rho family of small GTPases have emerged as key regulators of 
the actin cytoskeleton, and furthermore, through their interaction with multiple target 
proteins, they ensure coordinated control of cellular activities such as gene transcription 
and adhesion110 
Proper epithelial cell-to-cell require cadherin-based adherens junctions, which found to 
be associated with the actin cytoskeleton, and a recent study demonstrated that Rho is 
required for their assembly in keratinocytes110. It was in agreement with report where 
downregulation of Rho activity caused in fibroblasts nonmigratory and epithelioid 
phenotype. Restoration of Rho activity resulted in a migratory behavior and fibroblastoid 
phenotype111 
But what is interesting to our project, recent studies have implicated the small GTPase 
Rho and its downstream effector Rho kinase (ROK) in TGF-β1 induced remodeling of 
cell contacts in mammary epithelial cells, and as necessary components for the 
acquisition of stress fibers and a fibroblastic morphology in NMuMG and primary mouse 
keratinocytes20.  
In this study, we examined the possibility that PDE4 may influence EMT via Rho 
signaling. To our surprise, we found that TGF-β1 induced E-cadherin expression is 
potently suppressed by the Rho kinase inhibitor Y-27632. Interestingly, Y-27632 also 
decreased PDE4D expression, and subsequently, PDE4 activity (Fig. 4.14). Hence, to our 
knowledge, this is the first report of an alternative signaling pathway for TGF-β1 via 
RhoA activation in the positive regulation of EMT and negative regulation of PDE4 in 
alveolar epithelial cells.  
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5.5. Conclusions and future directions 
Phosphodiesterases are known propagators in many signaling pathways, including 
proliferation, migration, and differentiation32,112 thanks to their ability to hydrolyze 
cAMP and/or cGMP. PDE4 family of enzymes have proofed already their potential role 
in diseases in animal models and in clinical trials93. 
There is a growing interest in epithelial to mesenchymal transition, and especially its role 
in lung fibrosis and lung cancer1,5,10-13,23,24,76,113.  
In this investigation, we hypothesized that PDEs are altered during TGF-β1 
induced EMT. In order to explore this idea, an initial characterization of enzymes 
expression was performed. The upregulation of PDE4 family was demonstrated, which 
correlated with increased protein levels and elevation in PDE4 activity. The main PDE4 
family members influenced by TGF-β1 were PDE4A and PDE4D. Both PDE4A and 
PDE4D isoforms were localized in cytosol and membrane of the cells. Since PDE4 
family is cAMP specific and is the main one which contributed to total PDE activity in 
TGF-β1 induced EMT, this localization can be probably correlated with 
compartmelization of cAMP in the cell. In order to further investigations, cAMP level in 
the cells before and after TGF-β1 stimulation should be measured. 
Inhibition of PDE4 activity with specific inhibitor Rolipram, significantly attenuated 
TGF-β1 induced EMT – E-Cad which is believed to be the main epithelial phenotypic 
marker, was restored with Rolipram pre-treatment almost to control level. In pararel, 
fibronectin which is considering as one of the mesenchymal phenotypic marker, was 
abolished with Rolipram pre-treatment. These results strongly suggest that Rolipram has 
ability to reverse partially EMT in A549 cells. We couldn’t detect any effect of Rolipram 
on α-SMA. α-SMA is reported to be the main phenotypic marker of myofibroblast which 
according to hypothesis, are formed during idiopathic pulmonary fibrosis.  
To investigate specific PDE4 isoforms involvement in EMT process, siRNA experiments 
for PDE4A and PDD4D would be a good tool. 
Additionally, we observed that PDE4 inhibition had no influence on TGF-β1 Smad-
dependent pathway. This may suggest possibility that PDE4 inhibition resulted in reverse 
of EMT, influences alternative Smad-independent pathway. To make story complete it 
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would be interesting to investigate the RhoA, Ras, MAPK, PI3 kinase, Notch, and Wnt 
signaling pathways. 
We found that ROS is possible one of the main targets of PDE4 during TGF-β1 induced 
EMT. TGF-β1 increase ROS production, wheras Rolipram pre-treatment abolished this 
elevation. As one of the future directions, it would be a benefit to investigate in detail 
ROS signaling and the way how PDE4 is triggering ROS generation. It would be 
interesting to investigate whether there is any correlation between PKA and PKC, since 
PKA is strictly connected with PDE4 wheras PKC seems to be related to p47 pbox and 
NADPH oxidases. 
Moreover, we found out that Rho kinases and in particular its inhibition during TGF-β1 
induced EMT, are able to regulate PDE4. Additionally, Rho inhibition regulate EMT 
related epithelial marker E-Cad. To our knowledge, this is first report of an alternative 
signaling pathway for TGF-β1. Exploring in details how this correlation occurs would be 
interesting.  
Since all of this experiments were performed in A549 cells which is a cell line, it 
would be a benefit to perform similar set of experiments on freshly isolated primary cells 
according to pulmonary fibrosis, as well as on tumor cells according to lung cancer. It 
could be more relevant to human diseases and possible treatment. 
In conclusion, the current study provides new evidence for a biochemical and 
physiologically important role for PDE isoforms in the epithelial mesenchymal transition 
in alveolar epithelial cells. Based on its high level of expression and activity, PDE4 
appears to be a particularly useful marker of the phenotypic switch mediated by TGF-β1. 
The use of specific inhibitors targeted to cAMP hydrolyzing PDEs whose expression is 
increased during TGF-β1 induced EMT has the potential to provide a means to regulate 
the magnitude and duration of cAMP levels and response, and thereby to attenuate EMT. 
PDE4 selective inhibitors appear to be particularly attractive as novel therapeutics to 
attenuate EMT-associated lung diseases, such as pulmonary fibrosis and lung cancer. 
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Figure 5.1. Possible signaling pathway during PDE4 and/or Rho inhibition in TGF-β1 
induced EMT. 
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6. Appendix 
6.1. List of primers used for PCR amplification 
Gene Bank Acession 
Number 
 
 
Forward primer (5’-3’) 
 
Reverse primer (5’-3’) 
 
Annealing 
Temperature 
(˚C) 
Amplicon 
size (bp) 
alpha SMA human 
NM_001613.1 gagaagagttacgagttgcctga tgttagcatagaggtccttcctg 60 180 
cyt 19 human 
NM_002276.3 acttccgaaccaagtttgag cagcgtactgatttcctcct 56 185 
coll-1 human 
NM_000088 tctgactggaagagtggagagta gttcttgctgatgtaccagttct 58 153 
Desmin human 
NM_001927.3 gaggagattcagttgaaggaagaag gatctcctcttcatgcactttctta 60 156 
E-Cad human 
NM_004360 agaggtgggtgactacaaaatca agcaagagcagcagaatcagaat 60 213 
Fn-EDA human 
NM_212478.1 gagtacacagtcagtgtggttgc cgatatccagtgagctgaacatt 60 150 
GAPDH human 
M33197 caccgtcaaggctgagaac cagtagaggcagggatgatgtt 56 461 
ZO-1 human 
NM_003257 aagagaaaggtgaaacactgctg gtttgctccaacgagataatttg 60 158 
PDE1A human 
NM_001003683 ctggttggcttctacctttacac ctatgctctccacttgcttcatt 59 240 
PDE1C human 
NM_005020 gtcacttccaacaaatcaaagc ggtcacacagaggagaaaaagg 59 222 
PDE2A human 
NM_002599 atgctctgtgtccctgtcatc cttgagtttctgttccttctgga 59 183 
PDE3A human 
NM_000921 cctcacctctccaagggact acttctctccaggggctcat 59 236 
PDE3B human 
NM_000922 acagatgattctttgggattgg caggaaatggtgtgagaggatta 59 242 
PDE4A human 
NM_006202 ataactactccgaccgcatcc caataaaacccacctgagacttc 59 219 
PDE4D human 
NM_006203 tacacggagatgacttgattgtg tctgttatggtggctttgttga 59 246 
PDE5A human 
AY264918 ctattccctgttccttgtctgtg tgctttgtgtcttgtagcctgta 59 245 
PDE7A human 
L12052 cagtgggcttattgagagaatca caaatgtctgtgtctggtgtctt 59 192 
PDE7B human 
NM_018945 gttgagaggtgtggcgaaat tgtccaaggtagtcttcatccag 59 296 
PDE8A human 
NM_002605 gggtggatagagaagagttgtcc gactgatagcccattgttgtttc 59 265 
PDE8B human 
NM_003719 agagattttacggaccacagaac attgagagatacaagggggaaca 59 212 
PDE9A human 
AF067226 acctgatgggttcaagcagat tggacggacctcgttagagata 59 193 
PDE10A human 
NM_006661 gagatgaacgatttccaagagg gcacctgatgtattgctactgaa 59 207 
PDE11A human 
NM_016953 actgtgtaggtggcttttgaca cattgttggttcccctgtg 59 203 
Table 3. List of primers used for PCR amplification 
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6.2. List of primary antibodies 
Primary 
Antibody 
Source Dilution 
IB 
Dilution 
ICCH 
Company 
Anti - αSMA Mouse 
 
1:200 Sigma Aldrich 
Anti - cyt Mouse 1:1000 1:500 DakoCytomation 
Anti - desmin Rabbit 1:1000  Sigma 
Anti - E-cad Rabbit 1:1000 1:400 Upstate 
Anti - GAPDH Mouse 1:5000  Novus 
Anti - ERK 1/2 Rabbit 1:1000  Santa Cruz 
Anti - P-ERK 1/2 Rabbit 1:1000  Santa Cruz 
Anti - Fibronectin Rabbit 1:1000 1:200 Abcam 
Anti - PDE4A Rabbit 1:1000  Abcam 
Anti - PDE4D Rabbit 1:1000  Abcam 
Anti - SMAD4 Mouse 1:500  Santa Cruz 
Anti - SMAD2/3 Mouse 1:1000  BD Bioscences 
Anti - P-SMAD2 Rabbit 1:500  Cell Signaling 
Anti - P-SMAD3 Rabbit 1:500  Cell Signaling 
Anti - ROCK1 Rabbit 1:1000  Cell Signaling 
Anti - TGFβRII Rabbit 1:1000  Santa Cruz 
 
Table 4. List of primary antibodies  
 
 
6.3. List of secondary antibodies 
Secondary 
Antibody 
Dilution 
IB 
Dilution 
ICCH 
Company 
Alexa Fluor® 488 
goat anti–mouse IgG 
 1:1000 Molecular Probes 
Alexa Fluor® 488 
goat anti–rabbit IgG 
 1:1000 Molecular Probes 
HRP-conjugated 
anti-mouse IgG 
1:30000  Sigma 
HRP-conjugated 
anti-rabbit IgG 
1:30000  Sigma 
 
Table 5. List of secondary antibodies  
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